BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115-S120. [PMID: 14762851 DOI: 10.1002/lt.20034] [Cited by in Crossref: 459] [Cited by in F6Publishing: 424] [Article Influence: 25.5] [Reference Citation Analysis]
Number Citing Articles
1 Leong K, Kuppasani K, Pyrsopoulos N. Atrial tumor thrombus: A rare complication of hepatocellular carcinoma. Journal of the American Academy of Physician Assistants 2019;32:23-6. [DOI: 10.1097/01.jaa.0000552723.65316.80] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Parikh U, Marcus C, Sarangi R, Taghipour M, Subramaniam RM. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. PET Clin. 2015;10:327-343. [PMID: 26099670 DOI: 10.1016/j.cpet.2015.03.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
3 Schütte K, Zimmermann L, Bornschein J, Csepregi A, Rühl R, Ricke J, Malfertheiner P. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion. 2011;83:275-282. [PMID: 21282952 DOI: 10.1159/000320377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
4 Zhao Y, Fang Z, Luo J, Liu Q, Xu G, Pan H, Wei W, Yan Z. Evaluation of extrahepatic collateral arteries in hepatocellular carcinoma in three independent groups in a single center. Exp Ther Med 2015;10:2366-74. [PMID: 26668643 DOI: 10.3892/etm.2015.2822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
5 Stevens CL, Awad A, Abbas SM, Watters DAK. Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma. HPB (Oxford) 2017;19:653-8. [PMID: 28427829 DOI: 10.1016/j.hpb.2017.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
6 Fan HL, Hsieh CB, Chang WC, Huang SH, Chan DC, Yu JC, Chu CH, Chen TW. Advanced age is not a contraindication for liver resection in cases of large hepatocellular carcinoma. Eur J Surg Oncol 2014;40:214-9. [PMID: 24316111 DOI: 10.1016/j.ejso.2013.10.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
7 Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, Barraud H, Ayav A, Bronowicki JP, Peiffert D. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115:211-216. [PMID: 26028227 DOI: 10.1016/j.radonc.2015.04.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 11.7] [Reference Citation Analysis]
8 Lin WC, Lin YS, Chang CW, Chang CW, Wang TE, Wang HY, Chen MJ. Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. PLoS One. 2020;15:e0233212. [PMID: 32442193 DOI: 10.1371/journal.pone.0233212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Molina V, Sampson-Dávila J, Ferrer J, Fondevila C, Díaz Del Gobbo R, Calatayud D, Bruix J, García-Valdecasas JC, Fuster J. Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study. Surg Endosc 2018;32:2345-54. [PMID: 29218665 DOI: 10.1007/s00464-017-5930-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
10 Yang Y, Chang S, Zhao Z, Hou NI, He K, Wang X, Gao L, Wang L, Cai D, Guo BO, Tong D, Song T, Huang C. MicroRNA-214 suppresses the proliferation of human hepatocellular carcinoma cells by targeting E2F3. Oncol Lett 2015;10:3779-84. [PMID: 26788207 DOI: 10.3892/ol.2015.3745] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, Baytarian M, D'Addeo K, Fox R, Hunt K, Pocha C, Valderrama A, Taddei TH; VOCAL Study Group. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clin Gastroenterol Hepatol 2018;16:106-114.e5. [PMID: 28756056 DOI: 10.1016/j.cgh.2017.07.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
12 Sarpel U, Heskel M, Spivack JH, Feferman Y, Ang C, Gany F. Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status. J Health Care Poor Underserved 2018;29:1123-34. [PMID: 30122687 DOI: 10.1353/hpu.2018.0083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Qian GJ, Wang N, Shen Q, Sheng YH, Zhao JQ, Kuang M, Liu GJ, Wu MC. Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. Eur Radiol. 2012;22:1983-1990. [PMID: 22544225 DOI: 10.1007/s00330-012-2442-1] [Cited by in Crossref: 103] [Cited by in F6Publishing: 100] [Article Influence: 10.3] [Reference Citation Analysis]
14 Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl. 2009;15:1872-1881. [PMID: 19938138 DOI: 10.1002/lt.21954] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 6.2] [Reference Citation Analysis]
15 Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Transpl Int. 2013;26:109-118. [PMID: 22994652 DOI: 10.1111/j.1432-2277.2012.01562.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 9.0] [Reference Citation Analysis]
16 Nahon P, Sutton A, Rufat P, Charnaux N, Mansouri A, Moreau R, Ganne-Carrié N, Grando-Lemaire V, N’Kontchou G, Trinchet JC. A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis. J Hepatol. 2012;56:426-432. [PMID: 21907168 DOI: 10.1016/j.jhep.2011.08.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
17 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
18 Butt AS, Hamid S, Wadalawala AA, Ghufran M, Javed AA, Farooq O, Ahmed B, Ul Haq T, Jafri W. Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral-hepatocellular carcinoma. BMC Res Notes 2013;6:137. [PMID: 23566475 DOI: 10.1186/1756-0500-6-137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
19 Roayaie S, Jibara G, Taouli B, Schwartz M. Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol. 2013;20:3754-3760. [PMID: 23884750 DOI: 10.1245/s10434-013-3074-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
20 Saad ZM, Fouad Y, Ali LH, Hassanin TM. Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2020;21:2661-5. [PMID: 32986366 DOI: 10.31557/APJCP.2020.21.9.2661] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Nagarajan VK, Gogineni VR, White SB, Yu B. Real time evaluation of tissue optical properties during thermal ablation of ex vivo liver tissues. Int J Hyperthermia 2019;35:176-82. [PMID: 30130988 DOI: 10.1080/02656736.2018.1488278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
22 Lee YH, Hsu CY, Huang YH, Hsia CY, Chiou YY, Su CW, Lin HC, Huo TI. Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. J Clin Gastroenterol 2014;48:734-41. [PMID: 24100755 DOI: 10.1097/MCG.0b013e3182a8a254] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
23 Tsochatzis EA, Germani G, Burroughs AK. Transarterial Chemoembolization, Transarterial Chemotherapy, and Intra-arterial Chemotherapy for Hepatocellular Carcinoma Treatment. Seminars in Oncology 2010;37:89-93. [DOI: 10.1053/j.seminoncol.2010.03.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
24 Xiang X, Wang YY, Zhao LY, You XM, Li LQ. Extrahepatic metastasectomy for hepatocellular carcinoma: Predictors of long-term survival. J Surg Oncol 2017;115:504. [PMID: 28395121 DOI: 10.1002/jso.24556] [Reference Citation Analysis]
25 Brandi G, Venturi M, De Lorenzo S, Garuti F, Frega G, Palloni A, Garajovà I, Abbati F, Saccoccio G, Golfieri R, Pantaleo MA, Barbera MA. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases. Cancer Commun (Lond) 2018;38:41. [PMID: 29941039 DOI: 10.1186/s40880-018-0312-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Zhu SL, Ke Y, Peng YC, Ma L, Li H, Li LQ, Zhong JH. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. PLoS One. 2014;9:e115834. [PMID: 25541684 DOI: 10.1371/journal.pone.0115834.ecollection] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Kositamongkol P, Sanphasitvong V, Sirivatanauksorn Y, Pongpaibul A, Limsrichamrern S, Mahawithitwong P, Asavakarn S, Tovikkai C, Dumronggittigule W. Outcome of Liver Transplantation in Hepatocellular Carcinoma Patients at Siriraj Hospital. Transplant Proc 2017;49:1114-7. [PMID: 28583538 DOI: 10.1016/j.transproceed.2017.03.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol. 2014;21:3069-3076. [PMID: 24728740 DOI: 10.1245/s10434-014-3704-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
29 Mouli SK, Hickey R, Thornburg B, Sato KT, Desai K, Gabr A, Kallini JR, Niemeri H, Kircher S, Mulcahy MF, Benson Iii AB, Gupta R, Salem R, Lewandowski RJ. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. Journal of Vascular and Interventional Radiology 2016;27:1279-87. [DOI: 10.1016/j.jvir.2016.01.135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
30 Tang B, Du J, Wang J, Tan G, Gao Z, Wang Z, Wang L. Alpinetin suppresses proliferation of human hepatoma cells by the activation of MKK7 and elevates sensitization to cis-diammined dichloridoplatium. Oncol Rep 2012;27:1090-6. [PMID: 22159816 DOI: 10.3892/or.2011.1580] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
31 Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, Kirstein MM, Marquardt S, Rodt T. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2017;40:1559-66. [PMID: 28488104 DOI: 10.1007/s00270-017-1681-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
32 Kim T, Kim BW, Wang HJ, Lee HY, Won JH, Kim J, Hu XG, Sim J, Bang JB, Kim YB. Quantitative Assessment of the Portal Pressure for the Liver Surgery Using Serological Tests. Ann Surg 2016;264:330-8. [PMID: 26587849 DOI: 10.1097/SLA.0000000000001460] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
33 Chua TC, Morris DL. Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol. 2012;21:95-101. [PMID: 21397495 DOI: 10.1016/j.suronc.2011.01.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
34 Oikonomopoulos G, Aravind P, Sarker D. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma? Future Oncology 2016;12:465-76. [DOI: 10.2217/fon.15.341] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
35 Hesketh RL, Zhu AX, Oklu R. Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol 2015;21:78-84. [PMID: 25430530 DOI: 10.5152/dir.2014.14237] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
36 Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2007;13:391-399. [PMID: 17318865 DOI: 10.1002/lt.21095] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 9.5] [Reference Citation Analysis]
37 Lv WF, Liu KC, Lu D, Zhou CZ, Cheng DL, Xiao JK, Zhang XM, Zhang ZF. Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis. Cancer Manag Res 2018;10:4719-26. [PMID: 30410405 DOI: 10.2147/CMAR.S166527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
38 Lyytinen I, Lempinen M, Nordin A, Mäkisalo H, Stenman UH, Isoniemi H. Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma. Scand J Gastroenterol 2013;48:1066-73. [PMID: 23889187 DOI: 10.3109/00365521.2013.805810] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
39 Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 2021;21:1157. [PMID: 34715816 DOI: 10.1186/s12885-021-08904-3] [Reference Citation Analysis]
40 Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee FY, Lee SD. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl. 2011;17:556-566. [PMID: 21506244 DOI: 10.1002/lt.22273] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
41 Ferreira MV, Chaib E, Nascimento MU, Nersessian RS, Setuguti DT, D'Albuquerque LA. Liver transplantation and expanded Milan criteria: does it really work? Arq Gastroenterol 2012;49:189-94. [PMID: 23011240 DOI: 10.1590/s0004-28032012000300004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Andersen KJ, Grønbæk H, Villadsen GE, Knudsen AR, Ott P, Vildstrup H, Nielsen DT, Bharadwaz A. Chemoembolization of intermediate stage hepatocellular carcinomas: Results from a Nordic tertiary liver cancer center. Indian J Gastroenterol 2014;33:322-9. [DOI: 10.1007/s12664-013-0428-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Galanakis N, Kehagias E, Matthaiou N, Samonakis D, Tsetis D. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol 2018;5:HEP07. [PMID: 31293775 DOI: 10.2217/hep-2018-0001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
44 Chen L, Wang YB, Zhang YH, Gong JF, Li Y. Effective prediction of postoperative complications for patients after open hepatectomy: a simplified scoring system based on perioperative parameters. BMC Surg 2019;19:128. [PMID: 31488117 DOI: 10.1186/s12893-019-0597-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130-1137. [PMID: 15841454 DOI: 10.1002/hep.20688] [Cited by in Crossref: 244] [Cited by in F6Publishing: 227] [Article Influence: 14.4] [Reference Citation Analysis]
46 Amador A, Monforte NG, Bejarano N, Martí J, Artigau E, Navarro S, Fuster J. Cutaneous metastasis from hepatocellular carcinoma as the first clinical sign. J Hepatobiliary Pancreat Surg. 2007;14:328-330. [PMID: 17520212 DOI: 10.1007/s00534-006-1141-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
47 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
48 Lu XY, Xi T, Lau WY, Dong H, Xian ZH, Yu H, Zhu Z, Shen F, Wu MC, Cong WM. Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior. J Cancer Res Clin Oncol. 2011;137:567-575. [PMID: 20508947 DOI: 10.1007/s00432-010-0909-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
49 Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol. 2011;197:W562-W570. [PMID: 21940527 DOI: 10.2214/ajr.10.4379] [Cited by in Crossref: 109] [Cited by in F6Publishing: 45] [Article Influence: 9.9] [Reference Citation Analysis]
50 Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018;36:1913-1921. [PMID: 29498924 DOI: 10.1200/jco.2017.76.0892] [Cited by in Crossref: 218] [Cited by in F6Publishing: 99] [Article Influence: 54.5] [Reference Citation Analysis]
51 Berger Y, Spivack JH, Heskel M, Aycart SN, Labow DM, Sarpel U. Extrahepatic metastasectomy for hepatocellular carcinoma: Predictors of long-term survival. J Surg Oncol. 2016;114:469-474. [PMID: 27334650 DOI: 10.1002/jso.24340] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
52 DA Fonseca LG, Barroso-Sousa R, Bento AD, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:793-6. [PMID: 26171182 DOI: 10.3892/mco.2015.536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
53 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 94] [Article Influence: 2.3] [Reference Citation Analysis]
54 Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol 2014; 20(44): 16630-16638 [PMID: 25469032 DOI: 10.3748/wjg.v20.i44.16630] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
55 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
56 Graham JA, Melancon JK, Shetty K, Johnson LB. Liver transplantation should be offered to patients with small solitary hepatocellular carcinoma and a positive serum alpha fetoprotein rather than resection. Am J Surg 2013;205:374-80. [PMID: 23395581 DOI: 10.1016/j.amjsurg.2012.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
57 Piñero F, Marciano S, Fernández N, Silva J, Zambelo Y, Cobos M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Coronel M, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Rubinstein F, Silva M; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. Eur J Gastroenterol Hepatol 2018;30:376-83. [PMID: 29509603 DOI: 10.1097/MEG.0000000000001049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
58 Cheung TT, Ho CL, Lo CM, Chen S, Chan SC, Chok KS, Fung JY, Yan Chan AC, Sharr W, Yau T, Poon RT, Fan ST. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. J Nucl Med 2013;54:192-200. [PMID: 23321459 DOI: 10.2967/jnumed.112.107516] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
59 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. BMC Cancer 2017;17:279. [PMID: 28420329 DOI: 10.1186/s12885-017-3267-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
60 Nahon P, Sutton A, Rufat P, Ziol M, Thabut G, Schischmanoff PO, Vidaud D, Charnaux N, Couvert P, Ganne-Carrie N, Trinchet JC, Gattegno L, Beaugrand M. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology. 2008;134:102-110. [PMID: 18061182 DOI: 10.1053/j.gastro.2007.10.038] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 5.7] [Reference Citation Analysis]
61 Zhuang L, Wen T, Xu M, Yang J, Wang W, Wu H, Zeng Y, Yan L, Wei Y, Li B. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. Arch Med Sci 2017;13:1383-93. [PMID: 29181069 DOI: 10.5114/aoms.2017.71066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
62 Magistri P, Tarantino G, Guidetti C, Assirati G, Olivieri T, Ballarin R, Coratti A, Di Benedetto F. Laparoscopic versus robotic surgery for hepatocellular carcinoma: the first 46 consecutive cases. J Surg Res. 2017;217:92-99. [PMID: 28641762 DOI: 10.1016/j.jss.2017.05.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
63 Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583 [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Reference Citation Analysis]
64 Baldan A, Marino D, De Giorgio M, Angonese C, Cillo U, D'alessandro A, Masotto A, Massani M, Mazzucco M, Miola E, Neri D, Paccagnella D, Pivetta G, Stellato A, Tommasi L, Tremolada F, Tufano A, Zanus G, Farinati F; ON BEHALF OF GENE – GRUPPO EPATOCARCINOMA NORD-EST1. Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. Aliment Pharmacol Ther 2006;24:1495-501. [DOI: 10.1111/j.1365-2036.2006.03136.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
65 Bayram S, Akkız H, Topaktaş M. CHK2 1100delC, IVS2+1G>A and I157T mutations are not present in hepatocellular cancer cases from a Turkish population. Gene 2013;512:232-6. [DOI: 10.1016/j.gene.2012.10.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Ho CL, Chen S, Cheung SK, Leung TWT. Significant Value of 11C-Acetate and 18F-Fluorodeoxyglucose PET/Computed Tomography on 90Y Microsphere Radioembolization for Hepatocellular Carcinoma. PET Clinics 2019;14:459-67. [DOI: 10.1016/j.cpet.2019.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
67 Yim SY, Chun HS, Lee JS, Lim J, Kim TH, Kim BK, Kim SU, Park JY, Ahn SH, Kim GM, Won JY, Seo YS, Kim YH, Um SH, Kim DY. Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. Cancers 2022;14:385. [DOI: 10.3390/cancers14020385] [Reference Citation Analysis]
68 Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W. Sorafenib in the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Report of Four Cases. Korean J Gastroenterol 2015;65:246. [DOI: 10.4166/kjg.2015.65.4.246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Liu PH, Lee YH, Hsia CY, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014;21:1825-1833. [PMID: 24499831 DOI: 10.1245/s10434-014-3510-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
70 Ramani NS, Green LK. Metastatic hepatocellular carcinoma to the bone diagnosed by fine needle aspiration in a veteran population. Diagn Cytopathol 2022. [PMID: 35403368 DOI: 10.1002/dc.24961] [Reference Citation Analysis]
71 Beebe SJ. Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields. J Hepatocell Carcinoma 2015;2:49-55. [PMID: 27508194 DOI: 10.2147/JHC.S83941] [Reference Citation Analysis]
72 Harada K, Ishinuki T, Ohashi Y, Tanaka T, Chiba A, Numasawa K, Imai T, Hayasaka S, Tsugiki T, Miyanishi K, Nagayama M, Takemasa I, Kato J, Mizuguchi T. Nature of the liver volume depending on the gender and age assessing volumetry from a reconstruction of the computed tomography. PLoS One 2021;16:e0261094. [PMID: 34879120 DOI: 10.1371/journal.pone.0261094] [Reference Citation Analysis]
73 Wang C, Iyer SG, Low JK, Lin C, Wang S, Lu S, Chen C. Perioperative Factors Affecting Long-Term Outcomes of 473 Consecutive Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Ann Surg Oncol 2009;16:1832-42. [DOI: 10.1245/s10434-009-0448-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 7.9] [Reference Citation Analysis]
74 Baimas-George M, Watson M, Sulzer J, Salibi P, Murphy KJ, Levi D, Martinie JB, Vrochides D, Baker EH, Ocuin L, Iannitti DA. Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation. Surg Endosc 2021;35:3122-30. [PMID: 32588344 DOI: 10.1007/s00464-020-07747-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Le Roy B, Perrey A, Fontarensky M, Gagnière J, Abergel A, Pereira B, Lambert C, Boyer L, Pezet D, Chabrot P, Buc E. Combined Preoperative Portal and Hepatic Vein Embolization (Biembolization) to Improve Liver Regeneration Before Major Liver Resection: A Preliminary Report. World J Surg 2017;41:1848-56. [DOI: 10.1007/s00268-017-4016-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
76 Doğan T, Akhan Güzelcan E, Baumann M, Koyas A, Atas H, Baxendale IR, Martin M, Cetin-Atalay R. Protein domain-based prediction of drug/compound-target interactions and experimental validation on LIM kinases. PLoS Comput Biol 2021;17:e1009171. [PMID: 34843456 DOI: 10.1371/journal.pcbi.1009171] [Reference Citation Analysis]
77 Au KP, Chan SC, Chok KS, Chan AC, Cheung TT, Ng KK, Lo CM. Child-Pugh Parameters and Platelet Count as an Alternative to ICG Test for Assessing Liver Function for Major Hepatectomy. HPB Surg 2017;2017:2948030. [PMID: 28951631 DOI: 10.1155/2017/2948030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
78 Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, Pinelopi M, Burroughs AK. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8:1623-1641. [PMID: 18925854 DOI: 10.1586/14737140.8.10.1623] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
79 Amador A, Charco R, Martí J, Ferrer J, Mans E, Fondevila C, Fuster J, Visa J, Rimola A, Navasa M, Carlos García-valdecasas J, Grande L. Mil trasplantes hepáticos en el Hospital Clínic i Provincial de Barcelona. Cirugía Española 2005;78:231-7. [DOI: 10.1016/s0009-739x(05)70924-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Zeng Y, Zhang D, Wu M, Liu Y, Zhang X, Li L, Li Z, Han X, Wei X, Liu X. Lipid-AuNPs@PDA nanohybrid for MRI/CT imaging and photothermal therapy of hepatocellular carcinoma. ACS Appl Mater Interfaces 2014;6:14266-77. [PMID: 25090604 DOI: 10.1021/am503583s] [Cited by in Crossref: 117] [Cited by in F6Publishing: 106] [Article Influence: 14.6] [Reference Citation Analysis]
81 Hänsler J, Frieser M, Tietz V, Uhlke D, Wissniowski T, Bernatik T, Hothorn T, Hahn EG, Strobel D. Percutaneous Radiofrequency Ablation of Liver Tumors Using Multiple Saline-Perfused Electrodes. Journal of Vascular and Interventional Radiology 2007;18:405-10. [DOI: 10.1016/j.jvir.2006.12.729] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
82 Morise Z. Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease. Transl Gastroenterol Hepatol 2018;3:41. [PMID: 30148226 DOI: 10.21037/tgh.2018.07.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
83 Fujimori M, Takaki H, Nakatsuka A, Uraki J, Yamanaka T, Hasegawa T, Shiraki K, Takei Y, Sakuma H, Yamakado K. Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience. J Vasc Interv Radiol 2013;24:655-66. [PMID: 23428356 DOI: 10.1016/j.jvir.2012.12.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
84 Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Fidelman N. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36:1336-1343. [PMID: 23864021 DOI: 10.1007/s00270-013-0698-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
85 Reig M, Berzigotti A, Bruix J. If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection? Liver Int 2013;33:1454-6. [PMID: 24099263 DOI: 10.1111/liv.12273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Lambert B, de Klerk JM. Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun 2006;27:223-9. [PMID: 16479241 DOI: 10.1097/00006231-200603000-00004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
87 Kucuk ON, Soydal C, Araz M, Ozkan E, Aras G. Evaluation of the Response to Selective Internal Radiation Therapy in Patients With Hepatocellular Cancer According to Pretreatment 99mTc-MAA Uptake. Clinical Nuclear Medicine 2013;38:252-5. [DOI: 10.1097/rlu.0b013e31828162e8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
88 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
89 Wang J, Zhang Q, Shi F, Yadav DK, Hong Z, Wang J, Liang T, Bai X. A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma. Front Genet 2021;12:728476. [PMID: 34603388 DOI: 10.3389/fgene.2021.728476] [Reference Citation Analysis]
90 Cong WM, Wu MC. Small hepatocellular carcinoma: current and future approaches. Hepatol Int. 2013;7:805-812. [PMID: 26201917 DOI: 10.1007/s12072-013-9454-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
91 Cheng JW, Shi YH, Fan J, Huang XW, Qiu SJ, Xiao YS, Wang Z, Dai Z, Tang ZY, Zhou J. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137:1445-1453. [PMID: 21809031 DOI: 10.1007/s00432-011-1014-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
92 Löhe F, Angele MK, Gerbes AL, Löhrs U, Jauch KW, Schauer RJ. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol. 2005;31:994-999. [PMID: 16076546 DOI: 10.1016/j.ejso.2005.06.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
93 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
94 Bertelli R, Neri F, Tsivian M, Ruhrman N, Cavallari G, Beltempo P, Puviani L, DeVinci C, Pizza G, Nardo B. Endolymphatic immunotherapy in inoperable hepatocellular carcinoma. Transplant Proc. 2008;40:1913-1915. [PMID: 18675087 DOI: 10.1016/j.transproceed.2008.05.049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
95 Nguyen MH, Keeffe EB. General management. Best Practice & Research Clinical Gastroenterology 2005;19:161-74. [DOI: 10.1016/j.bpg.2004.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
96 Bayram S, Akkız H, Bekar A, Akgöllü E, Yıldırım S. The significance of Exonuclease 1 K589E polymorphism on hepatocellular carcinoma susceptibility in the Turkish population: a case-control study. Mol Biol Rep 2012;39:5943-51. [PMID: 22205538 DOI: 10.1007/s11033-011-1406-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
97 Morise Z. Developments and perspectives of laparoscopic liver resection in the treatment of hepatocellular carcinoma. Surg Today 2019;49:649-55. [PMID: 30649611 DOI: 10.1007/s00595-019-1765-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
98 Biederman DM, Titano JJ, Lee KM, Pierobon ES, Schwartz M, Facciuto ME, Gunasekaran G, Florman S, Fischman AM, Patel RS, Tabori NE, Nowakowski FS, Kim E. Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival. J Vasc Interv Radiol 2015;26:1630-8. [PMID: 26321014 DOI: 10.1016/j.jvir.2015.07.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
99 Yasui D, Murata S, Ueda T, Sugihara F, Onozawa S, Kawamoto C, Kumita S. Novel treatment strategy for advanced hepatocellular carcinoma: combination of conventional transcatheter arterial chemoembolization and modified method with portal vein occlusion for cases with arterioportal shunt: a preliminary study. Acta Radiol. 2018;59:266-274. [PMID: 28651444 DOI: 10.1177/0284185117717762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
100 Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014; 20(41): 15007-15017 [PMID: 25386049 DOI: 10.3748/wjg.v20.i41.15007] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
101 Fujimori M, Takaki H, Nakatsuka A, Uraki J, Yamanaka T, Hasegawa T, Shiraki K, Takei Y, Yamakado K. Combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe. J Vasc Interv Radiol. 2012;23:1622-1628. [PMID: 23177108 DOI: 10.1016/j.jvir.2012.09.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
102 Petersen J, Henninger B, Glodny B, Jaschke W. [Transarterial chemoembolisation in hepatocellular carcinoma]. Wien Med Wochenschr 2013;163:123-7. [PMID: 23413009 DOI: 10.1007/s10354-013-0180-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
103 Fathy AH, Bashandy MA, Bashandy SA, Mansour AM, Elsadek B. Sequential analysis and staging of a diethylnitrosamine-induced hepatocellular carcinoma in male Wistar albino rat model. Can J Physiol Pharmacol 2017;95:1462-72. [DOI: 10.1139/cjpp-2017-0413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
104 McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. Semin Intervent Radiol. 2013;30:49-55. [PMID: 24436517 DOI: 10.1055/s-0033-1333653] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
105 Welker MW, Lubomierski N, Gog C, Herrmann E, Engels K, Vogl TJ, Bechstein WO, Zeuzem S, Trojan J. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother 2010;22:205-11. [PMID: 20566428 DOI: 10.1179/joc.2010.22.3.205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
106 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
107 Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol. 2008;23:1259-1266. [PMID: 18699979 DOI: 10.1111/j.1440-1746.2008.05487.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
108 Toraih EA, Fawzy MS, El-Falouji AI, Hamed EO, Nemr NA, Hussein MH, Abd El Fadeal NM. Stemness-related transcriptional factors and homing gene expression profiles in hepatic differentiation and cancer. Mol Med 2016;22:653-63. [PMID: 27623812 DOI: 10.2119/molmed.2016.00096] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
109 Pirasteh A, Sorra EA, Marquez H, Sibley RC, Fielding JR, Vij A, Rich NE, Arroyo A, Yopp AC, Khatri G, Singal AG, Yokoo T. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. Abdom Radiol (NY) 2021;46:3708-16. [PMID: 33755735 DOI: 10.1007/s00261-021-03043-6] [Reference Citation Analysis]
110 Kritzinger J, Klass D, Ho S, Lim H, Buczkowski A, Yoshida E, Liu D. Hepatic embolotherapy in interventional oncology: technology, techniques, and applications. Clin Radiol 2013;68:1-15. [PMID: 22917735 DOI: 10.1016/j.crad.2012.06.112] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
111 Girardi DM, Pacífico JPM, Guedes de Amorim FPL, Dos Santos Fernandes G, Teixeira MC, Pereira AAL. Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals (Basel) 2020;14:28. [PMID: 33396181 DOI: 10.3390/ph14010028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
112 Graham J, Newman D, Smirniotopolous J, Shetty K, Slidell M, Johnson L. Transplantation for Hepatocellular Carcinoma in Younger Patients Has an Equivocal Survival Advantage as Compared With Resection. Transplantation Proceedings 2013;45:265-71. [DOI: 10.1016/j.transproceed.2012.07.151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
113 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Lee SS, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN). Radiology 2019;292:638-46. [PMID: 31287387 DOI: 10.1148/radiol.2019190183] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
114 Lima LDP, Machado CJ, Rodrigues JBSR, Vasconcellos LS, Junior EP, Vidigal PVT, Resende V. Immunohistochemical Coexpression of Epithelial Cell Adhesion Molecule and Alpha-Fetoprotein in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:5970852. [PMID: 30112355 DOI: 10.1155/2018/5970852] [Reference Citation Analysis]
115 Turgeon MK, Lee RM, Gamboa AC, Yopp A, Ryon EL, Goel N, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Maithel SK, Russell MC. Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. HPB (Oxford) 2021;23:422-33. [PMID: 32778389 DOI: 10.1016/j.hpb.2020.07.012] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Sotiropoulos GC, Lang H, Nadalin S, Neuhäuser M, Molmenti EP, Baba HA, Paul A, Saner FH, Weber F, Hilgard P, Frilling A, Broelsch CE, Malagó M. Liver Transplantation for Hepatocellular Carcinoma: University Hospital Essen Experience and Metaanalysis of Prognostic Factors. Journal of the American College of Surgeons 2007;205:661-75. [DOI: 10.1016/j.jamcollsurg.2007.05.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
117 Cheng J, Xie HY, Xu X, Wu J, Wei X, Su R, Zhang W, Lv Z, Zheng S, Zhou L. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011;310:35-45. [PMID: 21763068 DOI: 10.1016/j.canlet.2011.06.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 6.7] [Reference Citation Analysis]
118 Yoneda N, Matsui O, Kobayashi S, Kitao A, Kozaka K, Inoue D, Yoshida K, Minami T, Koda W, Gabata T. Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma. Jpn J Radiol. 2019;37:191-208. [PMID: 30712167 DOI: 10.1007/s11604-019-00817-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
119 Iwata H, Shibamoto Y, Hashizume C, Mori Y, Kobayashi T, Hayashi N, Kosaki K, Ishikawa T, Kuzuya T, Utsunomiya S. Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the novalis image-guided system: preliminary results regarding efficacy and toxicity. Technol Cancer Res Treat 2010;9:619-27. [PMID: 21070084 DOI: 10.1177/153303461000900610] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
120 Xie H, Xue YQ, Liu P, Zhang PJ, Tian ST, Yang Z, Guo Z, Wang HM. Multi-parameter gene expression profiling of peripheral blood for early detection of hepatocellular carcinoma. World J Gastroenterol 2018; 24(3): 371-378 [PMID: 29391759 DOI: 10.3748/wjg.v24.i3.371] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
121 Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062-1069. [PMID: 20233824 DOI: 10.1001/jama.2010.262] [Cited by in Crossref: 140] [Cited by in F6Publishing: 126] [Article Influence: 11.7] [Reference Citation Analysis]
122 Zaghloul RA, El-Shishtawy MM, El Galil KH, Ebrahim MA, Metwaly AA, Al-Gayyar MM. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. Eur J Pharmacol 2015;746:353-62. [PMID: 25449037 DOI: 10.1016/j.ejphar.2014.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
123 Feng Y, Li P, Liu Y, Sha Z, Feng L, Wang F, Mao Q, Xue W. The Association of Ala133Ser Polymorphism and Methylation in Ras Association Domain Family 1A Gene With Unfavorable Prognosis of Hepatocellular Carcinoma. Hepat Mon 2015;15:e32145. [PMID: 26587041 DOI: 10.5812/hepatmon.32145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
124 Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-radosavljevic M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial: . European Journal of Gastroenterology & Hepatology 2008;20:1012-9. [DOI: 10.1097/meg.0b013e3283036740] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
125 Sharifian M, Baharvand P, Moayyedkazemi A. Liver Cancer: New Insights into Surgical and Nonsurgical Treatments. CCTR 2021;17:197-206. [DOI: 10.2174/1573394717666210219104201] [Reference Citation Analysis]
126 Liu FY, Wang MQ, Duan F, Fan QS, Song P, Wang Y. Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization. BMC Gastroenterol 2013;13:105. [PMID: 23800233 DOI: 10.1186/1471-230X-13-105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
127 Tekbas A, Huebner J, Settmacher U, Dahmen U. Plants and Surgery: The Protective Effects of Thymoquinone on Hepatic Injury-A Systematic Review of In Vivo Studies. Int J Mol Sci 2018;19:E1085. [PMID: 29621129 DOI: 10.3390/ijms19041085] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
128 Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, Neuhaus R, Bahra M, Neuhaus P. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 11(10): 1420-1425 [PMID: 15770715 DOI: 10.3748/wjg.v11.i10.1420] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 57] [Article Influence: 3.7] [Reference Citation Analysis]
129 Metwaly HA, Al-Gayyar MM, Eletreby S, Ebrahim MA, El-Shishtawy MM. Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma. Sci Pharm. 2012;80:179-188. [PMID: 22396913 DOI: 10.3797/scipharm.1110-07] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
130 Espelund U, Grønbæk H, Villadsen GE, Simonsen K, Vestergaard PF, Jørgensen JO, Flyvbjerg A, Vilstrup H, Frystyk J. The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. Growth Horm IGF Res 2015;25:174-81. [PMID: 26068014 DOI: 10.1016/j.ghir.2015.05.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
131 Rode A. [Radiological treatment of hepatocellular carcinoma in 2010]. Cancer Radiother 2011;15:21-7. [PMID: 21257330 DOI: 10.1016/j.canrad.2010.11.002] [Reference Citation Analysis]
132 Pesi B, Ferrero A, Grazi GL, Cescon M, Russolillo N, Leo F, Boni L, Pinna AD, Capussotti L, Batignani G. Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study. Am J Surg. 2015;210:35-44. [PMID: 25935229 DOI: 10.1016/j.amjsurg.2014.09.041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
133 Tsochatzis EA, Fatourou EM, Triantos CK, Burroughs AK. Transarterial therapies for hepatocellular carcinoma. Recent Results Cancer Res 2013;190:195-206. [PMID: 22941022 DOI: 10.1007/978-3-642-16037-0_13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
134 Ochiai T, Ishii H, Toma A, Ishimoto T, Yamamoto Y, Morimura R, Ikoma H, Otsuji E. Modified high dorsal procedure for performing isolated anatomic total caudate lobectomy (with video). World J Surg Oncol 2016;14:132. [PMID: 27129389 DOI: 10.1186/s12957-016-0896-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
135 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol 2015; 7(15): 1913-1920 [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
136 Michalski CW, Billingsley KG. Modern technical approaches in resectional hepatic surgery. Surg Oncol Clin N Am 2015;24:57-72. [PMID: 25444469 DOI: 10.1016/j.soc.2014.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
137 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
138 Hayashi PH, Di Bisceglie AM. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Infect Dis Clin North Am 2006;20:1-25. [PMID: 16527646 DOI: 10.1016/j.idc.2006.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
139 Kothary N, Weintraub JL, Susman J, Rundback JH. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol. 2007;18:1517-1526; quiz 1527. [PMID: 18057286 DOI: 10.1016/j.jvir.2007.07.035] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 4.5] [Reference Citation Analysis]
140 Winters SD, Jackson S, Armstrong GA, Birchall IW, Lee KH, Low G. Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma. Clin Radiol. 2012;67:649-655. [PMID: 22300821 DOI: 10.1016/j.crad.2011.11.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
141 Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, Aslam T, Patanwala I, Gaggar S, Cole M, Sumpter K, Stewart S, Rose J, Hudson M, Manas D, Reeves HL. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110-117. [PMID: 23978719 DOI: 10.1016/j.jhep.2013.08.011] [Cited by in Crossref: 293] [Cited by in F6Publishing: 269] [Article Influence: 32.6] [Reference Citation Analysis]
142 Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 2010;30:166-174. [PMID: 19912531 DOI: 10.1111/j.1478-3231.2009.02166.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
143 Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333. [PMID: 31783782 DOI: 10.1186/s40425-019-0824-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 13.0] [Reference Citation Analysis]
144 Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2016;39:1580-1588. [PMID: 27586657 DOI: 10.1007/s00270-016-1426-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
145 Xu Y, Chen J, Wang H, Zheng H, Feng D, Zhang A, Leng J, Duan W, Yang Z, Chen M, Shi X, Cai S, Ji W, Jiang K, Zhang W, Chen Y, Gu W, Dong J, Lu S. Perioperative and long-term outcomes of liver resection for hepatitis B virus-related hepatocellular carcinoma without versus with hepatic inflow occlusion: study protocol for a prospective randomized controlled trial. Trials 2016;17:492. [PMID: 27724929 DOI: 10.1186/s13063-016-1621-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
146 Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, Zhao X, Zhang H, Liu S, Zhong Y. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014;61:840-849. [PMID: 24859455 DOI: 10.1016/j.jhep.2014.05.025] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 9.4] [Reference Citation Analysis]
147 Agüero F, Laguno M, Moreno A, Rimola A, Miró JM. Management of end-stage liver disease in HIV-infected patients: . Current Opinion in HIV and AIDS 2007;2:474-81. [DOI: 10.1097/coh.0b013e3282f0aadd] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
148 Tacher V, Duran R, Lin M, Sohn JH, Sharma KV, Wang Z, Chapiro J, Gacchina Johnson C, Bhagat N, Dreher MR, Schäfer D, Woods DL, Lewis AL, Tang Y, Grass M, Wood BJ, Geschwind JF. Multimodality Imaging of Ethiodized Oil-loaded Radiopaque Microspheres during Transarterial Embolization of Rabbits with VX2 Liver Tumors. Radiology 2016;279:741-53. [PMID: 26678453 DOI: 10.1148/radiol.2015141624] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
149 Liu C, Liang P, Liu F, Wang Y, Li X, Han Z, Liu C. MWA combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma. Int J Hyperthermia. 2011;27:654-662. [PMID: 21966941 DOI: 10.3109/02656736.2011.605099] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
150 Lu CX, Nan KJ, Nie YL, Hai YN, Jiao M. Delisheng, a Chinese medicinal compound, exerts anti-proliferative and pro-apoptotic effects on HepG2 cells through extrinsic and intrinsic pathways. Mol Biol Rep 2010;37:3407-12. [PMID: 20012371 DOI: 10.1007/s11033-009-9930-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
151 Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? Br J Cancer. 2018;118:248-257. [PMID: 29123264 DOI: 10.1038/bjc.2017.386] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
152 Löhe F, Angele MK, Rentsch M, Graeb C, Gerbes A, Löhrs U, Beuers U, Jauch KW. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant 2007;21:696-701. [PMID: 17988261 DOI: 10.1111/j.1399-0012.2007.00707.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
153 Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:425-33. [PMID: 19072390 DOI: 10.1586/17474124.2.3.425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
154 Shan SG, Gao YT, Xu YJ, Huang Y, Zhang Q, Zhai DK, Li JB, Wang FM, Jing X, Du Z, Wang YJ. Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients. Hepatol Res. 2013;43:1199-1210. [PMID: 23607749 DOI: 10.1111/hepr.12078] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
155 Uygun Ilikhan S, Bilici M, Sahin H, Demir Akca AS, Can M, Oz II, Guven B, Buyukuysal MC, Ustundag Y. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma. World J Gastroenterol 2015; 21(22): 6999-7007 [PMID: 26078578 DOI: 10.3748/wjg.v21.i22.6999] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
156 Chachá SGF, Gomes-Gouvêa MS, Malta FM, Ferreira SDC, Villanova MG, Souza FF, Teixeira AC, Passos ADDC, Pinho JRR, Martinelli ALC. Distribution of HBV subgenotypes in Ribeirão Preto, Southeastern Brazil: a region with history of intense Italian immigration. Braz J Infect Dis 2017;21:424-32. [PMID: 28482184 DOI: 10.1016/j.bjid.2017.01.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
157 Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-65. [PMID: 20501733 DOI: 10.1148/radiol.10091473] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 9.0] [Reference Citation Analysis]
158 Shalimar, Jain S, Gamanagatti SR, Kedia S, Thakur B, Nayak B, Kaur H, Gunjan D, Paul SB, Acharya SK. Role of Indocyanine Green in Predicting Post-Transarterial Chemoembolization Liver Failure in Hepatocellular Carcinoma. J Clin Exp Hepatol 2018;8:28-34. [PMID: 29743794 DOI: 10.1016/j.jceh.2017.05.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
159 Cho Y, Kim MS, Nam CM, Kang ES. Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Sci Rep 2019;9:1467. [PMID: 30728421 DOI: 10.1038/s41598-018-38110-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
160 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med. 2012;3:171-180. [PMID: 22969864 DOI: 10.3892/etm.2011.398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
161 Wang L, Wang L, Xu P, Liu C, Wang S, Luo X, Li M, Liu J, Zhao Z, Lai W, Luo F, Yan J. pH-Responsive Liposomes Loaded with Targeting Procoagulant Proteins as Potential Embolic Agents for Solid Tumor-Targeted Therapy. Mol Pharm 2022. [PMID: 35420039 DOI: 10.1021/acs.molpharmaceut.1c00912] [Reference Citation Analysis]
162 Xu Y, Gu L, Wang J, Wang Z, Zhang P, Zhang X. Detection of Circulating Antibodies to p16 Protein-Derived Peptides in Hepatocellular Carcinoma. Lab Med 2020;51:574-8. [PMID: 32195537 DOI: 10.1093/labmed/lmaa006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Steiner K, Papadopoulou A, Yu D. The role of interventional radiology in the treatment of hepatocellular carcinoma. Semin Ultrasound CT MR 2013;34:89-101. [PMID: 23395321 DOI: 10.1053/j.sult.2012.11.008] [Reference Citation Analysis]
164 Ormandy LA, Färber A, Cantz T, Petrykowska S, Wedemeyer H, Hörning M, Lehner F, Manns MP, Korangy F, Greten TF. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12(20): 3275-3282 [PMID: 16718852 DOI: 10.3748/wjg.v12.i20.3275] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
165 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012;63:159-169. [PMID: 22477032 DOI: 10.1007/s12013-012-9353-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
166 Bryant R, Laurent A, Tayar C, van Nhieu JT, Luciani A, Cherqui D. Liver resection for hepatocellular carcinoma. Surg Oncol Clin N Am 2008;17:607-33, ix. [PMID: 18486886 DOI: 10.1016/j.soc.2008.02.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
167 Wei Y, Dai F, Yi Y, Ye W, Zhao W. Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas. Oncol Lett 2018;16:5050-8. [PMID: 30250572 DOI: 10.3892/ol.2018.9263] [Reference Citation Analysis]
168 Majerović M, Jelaković M, Premužić M, Štromar IK, Radić D, Mance M, Pleština S, Ostojić R, Rustemović N, Krznarić Z. Hepatocellular Carcinoma Surveillance-Experience from Croatian Referral Centre for Chronic Liver Diseases. J Gastrointest Cancer 2019;50:48-53. [PMID: 29127665 DOI: 10.1007/s12029-017-0011-1] [Reference Citation Analysis]
169 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 12.5] [Reference Citation Analysis]
170 Toraih EA, Alghamdi SA, El-Wazir A, Hosny MM, Hussein MH, Khashana MS, Fawzy MS. Dual biomarkers long non-coding RNA GAS5 and microRNA-34a co-expression signature in common solid tumors. PLoS One 2018;13:e0198231. [PMID: 30289954 DOI: 10.1371/journal.pone.0198231] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
171 Helmberger T, Hoffmann RT, Jakobs T, Leibecke T, Lubienski A, Reiser M. [Liver tumor ablation]. Radiologe. 2005;45:55-62. [PMID: 15609015 DOI: 10.1007/s00117-004-1149-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
172 Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist. 2009;14:70-76. [PMID: 19144684 DOI: 10.1634/theoncologist.2008-0191] [Cited by in Crossref: 127] [Cited by in F6Publishing: 122] [Article Influence: 9.8] [Reference Citation Analysis]
173 Wang XD, Wang L, Ji FJ, Zhu JM, Ayana DA, Fang XD. Decreased CD27 on B lymphocytes in patients with primary hepatocellular carcinoma. J Int Med Res. 2012;40:307-316. [PMID: 22429370 DOI: 10.1177/147323001204000131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
174 Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl 2016;22:178-87. [PMID: 26479422 DOI: 10.1002/lt.24360] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
175 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509. [PMID: 17717454 DOI: 10.1097/sla.0b013e318148c704] [Cited by in Crossref: 331] [Cited by in F6Publishing: 103] [Article Influence: 22.1] [Reference Citation Analysis]
176 Tian Y, Liu Y, Qu J, Li K, Qin D, Huang A, Tang H. HBV regulated RhoC expression in HepG2.2.15 cells by enhancing its promoter activity: HBV regulated RhoC expression in HepG2.2.15 cells. J Basic Microbiol 2013;53:461-8. [DOI: 10.1002/jobm.201200063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
177 Pohlman RM, Turney MR, Wu PH, Brace CL, Ziemlewicz TJ, Varghese T. Two-dimensional ultrasound-computed tomography image registration for monitoring percutaneous hepatic intervention. Med Phys 2019;46:2600-9. [PMID: 31009079 DOI: 10.1002/mp.13554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
178 Strassburg CP, Becker T, Klempnauer J, Manns MP. [Liver transplantation: deciding between need and donor allocation]. Internist (Berl) 2004;45:1233-45. [PMID: 15517126 DOI: 10.1007/s00108-004-1295-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
179 Ray CE Jr, Brown AC, Green TJ, Winston H, Curran C, Kreidler SM, Glueck DH, Rochon PJ. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization. AJR Am J Roentgenol 2015;204:440-7. [PMID: 25615768 DOI: 10.2214/AJR.14.12844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
180 Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer. 2015;137:385-394. [PMID: 25529751 DOI: 10.1002/ijc.29394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
181 Bruguera M. Historia de la hepatología en Cataluña. Gastroenterología y Hepatología 2013;36:484-91. [DOI: 10.1016/j.gastrohep.2013.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
182 Zhang Q, Cheng S, Cao L, Yang J, Wang Y, Chen Y. LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway. Biosci Rep 2020;40:BSR20192790. [PMID: 32077915 DOI: 10.1042/BSR20192790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
183 Fan HL, Chen TW, Hsieh CB, Jan HC, His SC, De-Chuan C, Chu CH, Yu JC. Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria. Am J Surg 2010;200:252-7. [PMID: 20122677 DOI: 10.1016/j.amjsurg.2009.07.049] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
184 Kurtovic J, Riordan SM, Williams R. Liver transplantation for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:147-160. [PMID: 15757810 DOI: 10.1016/j.bpg.2004.10.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
185 Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949-59. [PMID: 21883324 DOI: 10.1111/j.1365-2036.2011.04823.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
186 Liu PH, Lee YH, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteria. Ann Surg Oncol. 2014;21:3835-3843. [PMID: 24903236 DOI: 10.1245/s10434-014-3831-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
187 Seinstra BA, Defreyne L, Lambert B, Lam MG, Verkooijen HM, van Erpecum KJ, van Hoek B, van Erkel AR, Coenraad MJ, Al Younis I. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials. 2012;13:144. [PMID: 22913492 DOI: 10.1186/1745-6215-13-144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
188 Zheng A, Zhang D, Wu M, Yang H, Liu X, Liu J. Multifunctional human serum albumin-modified reduced graphene oxide for targeted photothermal therapy of hepatocellular carcinoma. RSC Adv 2016;6:11167-75. [DOI: 10.1039/c5ra24785c] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
189 Tokumitsu Y, Tamesa T, Matsukuma S, Hashimoto N, Maeda Y, Tokuhisa Y, Sakamoto K, Ueno T, Hazama S, Ogihara H. An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. Int J Oncol. 2015;46:944-952. [PMID: 25524574 DOI: 10.3892/ijo.2014.2798] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
190 Yang LY, Chang RM, Lau WY, Ou DP, Wu W, Zeng ZJ. Mesohepatectomy for centrally located large hepatocellular carcinoma: Indications, techniques, and outcomes. Surgery. 2014;156:1177-1187. [PMID: 25444316 DOI: 10.1016/j.surg.2014.05.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
191 Shah SA, Tan JC, McGilvray ID, Cattral MS, Cleary SP, Levy GA, Greig PD, Grant DR. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2006;81:1633-1639. [PMID: 16794527 DOI: 10.1097/01.tp.0000226069.66819.7e] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
192 Sotiropoulos GC, Drühe N, Sgourakis G, Molmenti EP, Beckebaum S, Baba HA, Antoch G, Hilgard P, Radtke A, Saner FH, Nadalin S, Paul A, Malagó M, Broelsch CE, Lang H. Liver Transplantation, Liver Resection, and Transarterial Chemoembolization for Hepatocellular Carcinoma in Cirrhosis: Which Is the Best Oncological Approach? Dig Dis Sci 2009;54:2264-73. [DOI: 10.1007/s10620-008-0604-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
193 Dietrich CF, Teufel A, Sirlin CB, Dong Y. Surveillance of hepatocellular carcinoma by medical imaging. Quant Imaging Med Surg 2019;9:1904-10. [PMID: 31867241 DOI: 10.21037/qims.2019.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
194 Eissa LA, Eisa NH, Ebrahim MA, Ragab M, El-Gayar AM. Nitric Oxide is a Potential Diagnostic Marker for Hepatocellular Carcinoma. Sci Pharm 2013;81:763-75. [PMID: 24106672 DOI: 10.3797/scipharm.1307-09] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
195 Abdalla EK, Denys A, Hasegawa K, Leung TW, Makuuchi M, Murthy R, Ribero D, Zorzi D, Vauthey JN, Torzilli G. Treatment of large and advanced hepatocellular carcinoma. Ann Surg Oncol. 2008;15:979-985. [PMID: 18236115 DOI: 10.1245/s10434-007-9727-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
196 Shen JY, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. A simple prognostic score system predicts the prognosis of solitary large hepatocellular carcinoma following hepatectomy. Medicine (Baltimore) 2016;95:e4296. [PMID: 27495033 DOI: 10.1097/MD.0000000000004296] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
197 Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, Miller FH, Sato KT, Omary RA, Salem R. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009;49:1185-1193. [PMID: 19133645 DOI: 10.1002/hep.22747] [Cited by in Crossref: 185] [Cited by in F6Publishing: 162] [Article Influence: 14.2] [Reference Citation Analysis]
198 Yamashita N, Ohho A, Yamasaki A, Kurokawa M, Kotoh K, Kajiwara E. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol. 2014;49:1504-1513. [PMID: 24317936 DOI: 10.1007/s00535-013-0921-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
199 Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2016;34:2046-2053. [PMID: 26834067 DOI: 10.1200/jco.2015.64.0821] [Cited by in Crossref: 181] [Cited by in F6Publishing: 84] [Article Influence: 30.2] [Reference Citation Analysis]
200 Le Roy B, Gallon A, Cauchy F, Pereira B, Gagnière J, Lambert C, Yoh T, Boyer L, Pezet D, Buc E, Chabrot P. Combined biembolization induces higher hypertrophy than portal vein embolization before major liver resection. HPB (Oxford) 2020;22:298-305. [PMID: 31481315 DOI: 10.1016/j.hpb.2019.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
201 Kuang M, Lu MD, Xie XY, Xu HX, Xu ZF, Liu GJ, Yin XY, Huang JF, Lencioni R. Ethanol ablation of hepatocellular carcinoma Up to 5.0 cm by using a multipronged injection needle with high-dose strategy. Radiology. 2009;253:552-561. [PMID: 19709992 DOI: 10.1148/radiol.2532082021] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
202 Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:530-536. [PMID: 23216217 DOI: 10.1111/jgh.12087] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
203 Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer. 2009;9:389. [PMID: 19886989 DOI: 10.1186/1471-2407-9-389] [Cited by in Crossref: 84] [Cited by in F6Publishing: 91] [Article Influence: 6.5] [Reference Citation Analysis]
204 Yu X, Zheng Y, Zhu X, Gao X, Wang C, Sheng Y, Cheng W, Qin L, Ren N, Jia H, Dong Q. Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/Twist signaling pathway. Oncol Lett 2018;16:5299-308. [PMID: 30250599 DOI: 10.3892/ol.2018.9281] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
205 Guarino M, Stroffolini T, Lombardo FL, Loperto I, Auriemma F, Gentile I, Caporaso N, Morisco F. Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. J Med Virol 2015;87:1368-76. [PMID: 25802203 DOI: 10.1002/jmv.24187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
206 Shah SA, Cleary SP, Tan JC, Wei AC, Gallinger S, Grant DR, Greig PD. An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol. 2007;14:2608-2614. [PMID: 17522942 DOI: 10.1245/s10434-007-9443-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.9] [Reference Citation Analysis]
207 Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143-1152. [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
208 Amador A, Charco R, Martí J, Ferrer J, Mans E, Fondevila C, Fuster J, Grande L, Visa J, Rimola A, Navasa M, Carlos García-valdecasas J. One Thousand Liver Transplants: The Hospital Clinic Experience. Transplantation Proceedings 2005;37:3916-8. [DOI: 10.1016/j.transproceed.2005.09.167] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
209 Sahin H, Harman M, Cinar C, Bozkaya H, Parildar M, Elmas N. Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging. J Vasc Interv Radiol. 2012;23:241-247. [PMID: 22019180 DOI: 10.1016/j.jvir.2011.08.030] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
210 Li K, Xia C, Wang B, Chen H, Wang T, He Q, Cao H, Wang Y. Effects of quantum dots on the ROS amount of liver cancer stem cells. Colloids and Surfaces B: Biointerfaces 2017;155:193-9. [DOI: 10.1016/j.colsurfb.2017.04.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
211 Tellapuri S, Sutphin PD, Beg MS, Singal AG, Kalva SP. Staging systems of hepatocellular carcinoma: A review. Indian J Gastroenterol 2018;37:481-91. [DOI: 10.1007/s12664-018-0915-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
212 Ishikawa K, Chiba T, Ooka Y, Suzuki E, Ogasawara S, Maeda T, Yokoyama M, Inoue M, Wakamatsu T, Kusakabe Y, Saito T, Tawada A, Arai M, Kanda T, Maruyama H, Imazeki F, Kato N. Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. Oncotarget 2018;9:21560-8. [PMID: 29765560 DOI: 10.18632/oncotarget.25108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
213 Belghiti J, Kianmanesh R. Surgical treatment of hepatocellular carcinoma. HPB (Oxford). 2005;7:42-49. [PMID: 18333160 DOI: 10.1080/13651820410024067] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
214 Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263:590-599. [PMID: 22438359 DOI: 10.1148/radiol.12111550] [Cited by in Crossref: 126] [Cited by in F6Publishing: 131] [Article Influence: 12.6] [Reference Citation Analysis]
215 Ecker BL, Hoteit MA, Forde KA, Hsu CC, Reddy KR, Furth EE, Siegelman ES, Habibollahi P, Ben-Josef E, Porrett PM, Abt PL, Shaked A, Olthoff KM, Levine MH. Patterns of Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Posttransplant Pathologic Stage: A Contemporary Appraisal of the Milan Criteria. Transplantation. 2018;102:648-655. [PMID: 29319629 DOI: 10.1097/tp.0000000000002056] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
216 Waneck F. [Targeted radiological therapy of liver tumors]. Radiologe 2015;55:43-7. [PMID: 25609580 DOI: 10.1007/s00117-014-2707-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
217 Tapper EB, Catana AM, Sethi N, Mansuri D, Sethi S, Vong A, Afdhal NH. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer 2016;122:852-8. [PMID: 26716758 DOI: 10.1002/cncr.29855] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
218 Han YS, Choi DL, Park JB. Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation--eighteen months of follow-up: a case report. Transplant Proc. 2008;40:2835-2836. [PMID: 18929876 DOI: 10.1016/j.transproceed.2008.07.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
219 Parolin MB, Coelho JCU, Matias JEF, Baretta GAP, Ioshii SO, Nardo H. Resultados do transplante hepático em pacientes com diagnóstico pré-operatório de hepatocarcinoma. Arq Gastroenterol 2006;43:259-64. [DOI: 10.1590/s0004-28032006000400003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
220 Chachá SGF, Gomes-Gouvêa MS, Malta FM, Ferreira SDC, Villanova MG, Souza FF, Teixeira AC, Passos ADDC, Pinho JRR, Martinelli ALC. Basal core promoter and precore mutations among hepatitis B virus circulating in Brazil and its association with severe forms of hepatic diseases. Mem Inst Oswaldo Cruz 2017;112:626-31. [PMID: 28902288 DOI: 10.1590/0074-02760160540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
221 Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-5742. [PMID: 19805671 DOI: 10.1200/jco.2009.23.1282] [Cited by in Crossref: 155] [Cited by in F6Publishing: 73] [Article Influence: 11.9] [Reference Citation Analysis]
222 Yamada K, Suda T, Komoro YS, Kanefuji T, Kubota T, Murayama T, Nakayama H, Aoyagi Y. Low fat intake is associated with pathological manifestations and poor recovery in patients with hepatocellular carcinoma. Nutr J 2013;12:79. [PMID: 23758691 DOI: 10.1186/1475-2891-12-79] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
223 Choi SH, Byun JH, Lim Y, Lee SJ, Kim SY, Won HJ, Shin YM, Kim P. Liver Imaging Reporting and Data System: Patient Outcomes for Category 4 and 5 Nodules. Radiology 2018;287:515-24. [DOI: 10.1148/radiol.2018170748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
224 Kang JH, Choi SH, Lee JS, Park SH, Kim KW, Kim SY, Lee SS, Byun JH. Interreader Agreement of Liver Imaging Reporting and Data System on MRI: A Systematic Review and Meta‐Analysis. J Magn Reson Imaging 2020;52:795-804. [DOI: 10.1002/jmri.27065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
225 Li L, Diao W, Zen K. Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:21-33. [PMID: 27508173 DOI: 10.2147/JHC.S44463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
226 Li K, Wang HT, He YK, Guo T. New idea for treatment strategies for Barcelona Clinic Liver Cancer stages based on a network meta-analysis. Medicine (Baltimore) 2017;96:e6950. [PMID: 28514316 DOI: 10.1097/MD.0000000000006950] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
227 Murad HY, Bortz EP, Yu H, Luo D, Halliburton GM, Sholl AB, Khismatullin DB. Phenotypic alterations in liver cancer cells induced by mechanochemical disruption. Sci Rep 2019;9:19538. [PMID: 31862927 DOI: 10.1038/s41598-019-55920-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
228 Weismüller TJ, Negm A, Becker T, Barg-hock H, Klempnauer J, Manns MP, Strassburg CP. The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transplant International 2009;22:970-8. [DOI: 10.1111/j.1432-2277.2009.00915.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
229 Yang YP, Qu JH, Chang XJ, Lu YY, Bai WL, Dong Z, Wang H, An LJ, Xu ZX, Wang CP. High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. J Transl Med. 2013;11:41. [PMID: 23414367 DOI: 10.1186/1479-5876-11-41] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
230 Capussotti L, Ferrero A, Viganò L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg 2006;30:992-9. [PMID: 16736327 DOI: 10.1007/s00268-005-0524-9] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 5.9] [Reference Citation Analysis]
231 Watchmaker JM, Lipnik AJ, Fritsche MR, Baker JC, Mouli SK, Geevarghese S, Banovac F, Omary RA, Brown DB. Are prophylactic antibiotics necessary prior to transarterial chemoembolization for hepatocellular carcinoma in patients with native biliary anatomy? J Surg Oncol 2018;117:1312-7. [DOI: 10.1002/jso.24993] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
232 Zakaria HM, Macshut M, Gaballa NK, Sherif AE, Abdel-Samea ME, Abdel-Samiee M, Marwan I, Yassein T. Total tumor volume as a prognostic value for survival following liver resection in patients with hepatocellular carcinoma. Retrospective cohort study. Ann Med Surg (Lond) 2020;54:47-53. [PMID: 32368340 DOI: 10.1016/j.amsu.2020.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
233 Allemann P, Demartines N, Bouzourene H, Tempia A, Halkic N. Long-term outcome after liver resection for hepatocellular carcinoma larger than 10 cm. World J Surg. 2013;37:452-458. [PMID: 23188527 DOI: 10.1007/s00268-012-1840-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
234 Chen G, Li X, Yang J, Li J, Wang X, He J, Huang Z. Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis. Arch Med Sci. 2016;12:1110-1117. [PMID: 27695503 DOI: 10.5114/aoms.2016.61916] [Cited by in Crossref: 15] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
235 Hirakawa M, Yoshimitsu K, Irie H, Tajima T, Nishie A, Asayama Y, Ishigami K, Kakihara D, Taketomi A, Aishima S, Honda H. Performance of radiological methods in diagnosing hepatocellular carcinoma preoperatively in a recipient of living related liver transplantation: comparison with step section histopathology. Jpn J Radiol 2011;29:129-37. [DOI: 10.1007/s11604-010-0528-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
236 Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ, Lam VW. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford). 2012;14:285-290. [PMID: 22487065 DOI: 10.1111/j.1477-2574.2012.00446.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 6.1] [Reference Citation Analysis]
237 Papaconstantinou I, Karakatsanis A, Gazouli M, Polymeneas G, Voros D. The role of microRNAs in liver cancer. Eur J Gastroenterol Hepatol 2012;24:223-8. [PMID: 22228372 DOI: 10.1097/MEG.0b013e3283505063] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
238 op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One. 2012;7:e45066. [PMID: 23071507 DOI: 10.1371/journal.pone.0045066] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
239 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Loong CC, Chiou YY, Huo TI. Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Dig Liver Dis 2012;44:868-74. [PMID: 22647396 DOI: 10.1016/j.dld.2012.04.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
240 Leal CRG, Magalhães C, Barbosa D, Aquino D, Carvalho B, Balbi E, Pacheco L, Perez R, de Tarso Pinto P, Setubal S. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 2018;36:911-8. [PMID: 29948358 DOI: 10.1007/s10637-018-0621-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
241 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI, Lee SD. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int 2013;7:645-54. [PMID: 26201797 DOI: 10.1007/s12072-012-9375-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
242 Chen C, Liu P, Lee Y, Tsai Y, Hsu C, Huang Y, Chiou Y, Huo T. Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation: Radiofrequency ablation in renal insufficiency. J Gastroenterol Hepatol 2015;30:192-8. [DOI: 10.1111/jgh.12669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
243 Federico P, Giunta EF, Pappalardo A, Tufo A, Marte G, Attademo L, Fabbrocini A, Petrillo A, Daniele B. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel) 2021;14:233. [PMID: 33800217 DOI: 10.3390/ph14030233] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Luciani A, Vignaud A, Cavet M, Nhieu JT, Mallat A, Ruel L, Laurent A, Deux JF, Brugieres P, Rahmouni A. Liver cirrhosis: intravoxel incoherent motion MR imaging--pilot study. Radiology. 2008;249:891-899. [PMID: 19011186 DOI: 10.1148/radiol.2493080080] [Cited by in Crossref: 480] [Cited by in F6Publishing: 468] [Article Influence: 34.3] [Reference Citation Analysis]
245 Risse JH, Pauleit D, Bender H, Rabe C, Fischer H, Biersack H, Bucerius J. 18 F-FDG-PET and Histopathology in 131 I-Lipiodol Treatment for Primary Liver Cancer. Cancer Biotherapy and Radiopharmaceuticals 2009;24:445-52. [DOI: 10.1089/cbr.2008.0560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
246 Wang F, Jing X, Li G, Wang T, Yang B, Zhu Z, Gao Y, Zhang Q, Yang Y, Wang Y, Wang P, Du Z. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. Liver Int. 2012;32:644-655. [PMID: 22118340 DOI: 10.1111/j.1478-3231.2011.02675.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
247 Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology 2010;138:52-64. [DOI: 10.1053/j.gastro.2009.09.006] [Cited by in Crossref: 650] [Cited by in F6Publishing: 569] [Article Influence: 54.2] [Reference Citation Analysis]
248 Okuda Y, Mizuno S, Shiraishi T, Murata Y, Tanemura A, Azumi Y, Kuriyama N, Kishiwada M, Usui M, Sakurai H, Tabata M, Yamada T, Isaji S. Clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C hepatocellular carcinoma patients with comparison to hepatitis B or C virus. Biomed Res Int 2014;2014:975380. [PMID: 24745029 DOI: 10.1155/2014/975380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
249 Earl TM, Chapman WC. Conventional Surgical Treatment of Hepatocellular Carcinoma. Clinics in Liver Disease 2011;15:353-70. [DOI: 10.1016/j.cld.2011.03.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
250 Huang Y, Wang FM, Wang T, Wang YJ, Zhu ZY, Gao YT, Du Z. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients. Digestion. 2012;86:329-337. [PMID: 23207161 DOI: 10.1159/000342801] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
251 Federico P, Petrillo A, Giordano P, Bosso D, Fabbrocini A, Ottaviano M, Rosanova M, Silvestri A, Tufo A, Cozzolino A, Daniele B. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers (Basel) 2020;12:E3025. [PMID: 33080958 DOI: 10.3390/cancers12103025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
252 Tokumitsu Y, Sakamoto K, Tokuhisa Y, Matsui H, Matsukuma S, Maeda Y, Sakata K, Wada H, Eguchi H, Ogihara H, Fujita Y, Hamamoto Y, Iizuka N, Ueno T, Nagano H. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett 2018;15:4411-22. [PMID: 29556288 DOI: 10.3892/ol.2018.7821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
253 Kuang M, Xie XY, Huang C, Wang Y, Lin MX, Xu ZF, Liu GJ, Lu MD. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. J Gastrointest Surg. 2011;15:2165-2171. [PMID: 21972056 DOI: 10.1007/s11605-011-1716-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
254 Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A 3rd, Nemcek AA Jr, Gates VL, Abecassis M, Omary RA, Salem R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81. [PMID: 18027884 DOI: 10.1002/hep.21980] [Cited by in Crossref: 401] [Cited by in F6Publishing: 362] [Article Influence: 28.6] [Reference Citation Analysis]
255 Mohkam K, Rayar M, Adam JP, Muscari F, Rode A, Merle P, Pradat P, Bauler S, Delfour I, Chiche L, Ducerf C, Boudjema K, Lesurtel M, Laurent C, Mabrut JY. Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT). BMC Cancer 2018;18:844. [PMID: 30139340 DOI: 10.1186/s12885-018-4667-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
256 Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, Florman SS. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology. 2015;61:895-904. [PMID: 25099130 DOI: 10.1002/hep.27358] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
257 Sotiropoulos GC, Lang H, Sgourakis G, Nadalin S, Molmenti EP, Radtke A, Paul A, Beckebaum S, Saner FH, Baba HA, Gerken G, Malagó M, Broelsch CE. Liberal Policy in Living Donor Liver Transplantation for Hepatocellular Carcinoma: Lessons Learned. Dig Dis Sci 2009;54:377-84. [DOI: 10.1007/s10620-008-0319-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
258 Kim DH, Choi SH, Byun JH, Kang JH, Lim YS, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. J Hepatol 2019;71:534-42. [PMID: 31108157 DOI: 10.1016/j.jhep.2019.05.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
259 Jang JK, Choi SH, Byun JH, Park SY, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. New strategy for Liver Imaging Reporting and Data System category M to improve diagnostic performance of MRI for hepatocellular carcinoma ≤ 3.0 cm. Abdom Radiol (NY) 2022. [PMID: 35523888 DOI: 10.1007/s00261-022-03538-w] [Reference Citation Analysis]
260 Lambert B, Van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2005;32:980-989. [PMID: 16032439 DOI: 10.1007/s00259-005-1859-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
261 Martinez-Mier G, Esquivel-Torres S, Medina Granados JP, Luna-Castillo M, Castillo-Chiquete R, Calzada-Grijalva JF, Gonzalez-Velazquez F. [Presentation, staging, and outcome of patients with hepatocellular carcinoma at a center in Veracruz, Mexico]. Rev Gastroenterol Mex 2014;79:171-9. [PMID: 25236795 DOI: 10.1016/j.rgmx.2014.05.007] [Reference Citation Analysis]
262 Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HL. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. Hepatol Commun 2021. [PMID: 34796691 DOI: 10.1002/hep4.1847] [Reference Citation Analysis]
263 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
264 Eisa NH, Ebrahim MA, Ragab M, Eissa LA, El-Gayar AM. Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma. J Oncol Pharm Pract 2015;21:323-30. [PMID: 24769518 DOI: 10.1177/1078155214532698] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
265 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
266 Cho ES, Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol. 2015;16:449-464. [PMID: 25995679 DOI: 10.3348/kjr.2015.16.3.449] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
267 Devcic Z, Elboraey M, Vidal L, Mody K, Harnois D, Patel T, Toskich BB. Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. Semin Intervent Radiol 2019;36:287-97. [PMID: 31680719 DOI: 10.1055/s-0039-1698755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Hayashi PH, Di Bisceglie AM. The progression of hepatitis B– and C–infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Medical Clinics of North America 2005;89:345-69. [DOI: 10.1016/j.mcna.2004.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
269 Burkhart RA, Pawlik TM. Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729235. [PMID: 28975828 DOI: 10.1177/1073274817729235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
270 Cheng J, Gao F, Chen X, Wu J, Xing C, Lv Z, Xu W, Xie Q, Wu L, Ye S, Xie H, Zheng S, Zhou L. Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy. Mol Carcinog 2014;53:820-32. [PMID: 23661548 DOI: 10.1002/mc.22040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
271 McGrane S, McSweeney SE, Maher MM. Which patients will benefit from percutaneous radiofrequency ablation of colorectal liver metastases? Critically appraised topic. Abdom Imaging. 2008;33:48-53. [PMID: 17874263 DOI: 10.1007/s00261-007-9313-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
272 Chung WS, Lee KH, Park MS, Lee YJ, Kwon J, Baek SE, Kim MJ. Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. AJR Am J Roentgenol. 2012;199:349-359. [PMID: 22826396 DOI: 10.2214/ajr.11.7563] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
273 Zhang YA, Zhu CW. Management of advanced hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(12): 1250-1254 [DOI: 10.11569/wcjd.v18.i12.1250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
274 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 153] [Article Influence: 19.1] [Reference Citation Analysis]
275 Kwee SA, Wong LL, Hernandez BY, Chan OT, Sato MM, Tsai N. Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by [(18)F]fluorocholine PET/CT. Diagnostics (Basel) 2015;5:189-99. [PMID: 26090216 DOI: 10.3390/diagnostics5020189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
276 Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, Ren Z, Ye SL. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23:787-793. [PMID: 21730869 DOI: 10.1097/meg.0b013e32834902dd] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
277 Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33:532-540. [PMID: 19847482 DOI: 10.1007/s00270-009-9728-y] [Cited by in Crossref: 92] [Cited by in F6Publishing: 76] [Article Influence: 7.1] [Reference Citation Analysis]
278 Lindquester WS, Dhangana R, Pinter J, Warhadpande S, Bandi R. Percutaneous ablation versus surgical ablation and resection of liver tumors: medicare volume and physician reimbursement trends from 2010 to 2018. Abdom Radiol (NY) 2021;46:4056-61. [PMID: 33772616 DOI: 10.1007/s00261-021-03054-3] [Reference Citation Analysis]
279 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
280 Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L, Liu W, Li B, Meng S, Xiong W, Mi J. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases. Theranostics 2021;11:6006-18. [PMID: 33897895 DOI: 10.7150/thno.59841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
281 Yen Y, Changchien C, Wang J, Kee K, Hung C, Hu T, Lee C, Lin C, Wang C, Chen T, Huang Y, Lu S. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Digestive and Liver Disease 2009;41:431-41. [DOI: 10.1016/j.dld.2008.11.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
282 Song Y, Cao L. N-myc downstream-regulated gene 1: Diverse and complicated functions in human hepatocellular carcinoma (Review). Oncol Lett 2013;6:1539-42. [PMID: 24260043 DOI: 10.3892/ol.2013.1636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
283 Carr BI. Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape. Hepatoma Res 2019;5:3. [PMID: 30842979 DOI: 10.20517/2394-5079.2018.113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
284 Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141:330-339. [PMID: 17349844 DOI: 10.1016/j.surg.2006.06.028] [Cited by in Crossref: 258] [Cited by in F6Publishing: 253] [Article Influence: 16.1] [Reference Citation Analysis]
285 Pivonello C, Negri M, De Martino MC, Napolitano M, de Angelis C, Provvisiero DP, Cuomo G, Auriemma RS, Simeoli C, Izzo F, Colao A, Hofland LJ, Pivonello R. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget 2016;7:9718-31. [PMID: 26756219 DOI: 10.18632/oncotarget.6836] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
286 Toraih EA, Ellawindy A, Fala SY, Al Ageeli E, Gouda NS, Fawzy MS, Hosny S. Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma. Biomed Pharmacother 2018;102:653-69. [PMID: 29604585 DOI: 10.1016/j.biopha.2018.03.105] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
287 Tourky M, Youssef A, Salman M, Abouelregal T, Tag El-Din M, Moustafa A, Taha A, El-Mikkawy A, Saadawy A, Salman A. Portal venous pressure in non-cirrhotic bilharzial patients undergoing elective splenectomy, can it affect mortality? A prospective study. Acta Gastroenterol Belg 2021;84:549-56. [PMID: 34965035 DOI: 10.51821/84.4.004] [Reference Citation Analysis]
288 Chidi AP, Bryce CL, Myaskovsky L, Fine MJ, Geller DA, Landsittel DP, Tsung A. Differences in Physician Referral Drive Disparities in Surgical Intervention for Hepatocellular Carcinoma: A Retrospective Cohort Study. Ann Surg 2016;263:362-8. [PMID: 25563883 DOI: 10.1097/SLA.0000000000001111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
289 Chow PK. Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria? J Gastroenterol Hepatol. 2012;27:452-457. [PMID: 22142283 DOI: 10.1111/j.1440-1746.2011.07034.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
290 Di Benedetto F, De Ruvo N, Berretta M, Masetti M, Montalti R, Di Sandro S, Ballarin R, Codeluppi M, Guaraldi G, Gerunda GE. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008;34:422-7. [PMID: 17590564 DOI: 10.1016/j.ejso.2007.05.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
291 Nakano M, Ando E, Kuromatsu R, Torimura T, Sumie S, Takata A, Fukushima N, Kurogi J, Niizeki T, Iwamoto H, Tanaka M, Sata M. Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan: Recent progress in surveillance for liver cancer. Hepatology Research 2010;40:989-96. [DOI: 10.1111/j.1872-034x.2010.00706.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
292 Marelli L, Shusang V, Senzolo M, Cholongitas E, Goode A, Yu D, Patch DW, Burroughs AK. Repeated courses of transarterial embolization with polyvinyl alcohol particles: 'long life elixir' in a cirrhotic patient with unresectable hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2007;19:329-32. [PMID: 17353698 DOI: 10.1097/MEG.0b013e3280298391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
293 Atta MM, El-masry SA, Abdel-hameed M, Baiomy HA, Ramadan NE. Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma. Clinical Biochemistry 2008;41:1131-9. [DOI: 10.1016/j.clinbiochem.2008.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
294 Robles R, Marín C, López-Conesa A, Capel A, Parrilla P. [Chemical embolisation before laparoscopic hepatic resection in early hepatocellular carcinoma in cirrhotic patients]. Cir Esp 2009;86:303-7. [PMID: 19800616 DOI: 10.1016/j.ciresp.2009.06.004] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
295 Ahronian LG, Driscoll DR, Klimstra DS, Lewis BC. The p53R172H mutant does not enhance hepatocellular carcinoma development and progression. PLoS One 2015;10:e0123816. [PMID: 25885474 DOI: 10.1371/journal.pone.0123816] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
296 Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15:285-292. [PMID: 20203173 DOI: 10.1634/theoncologist.2009-0316] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 5.7] [Reference Citation Analysis]
297 Cholongitas E, Burroughs AK, Dhillon AP. Liver Biopsy. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 762-70. [DOI: 10.1002/9781444314403.ch46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
298 Ni JY, Kong J, Sun HL, Chen YT, Luo JH, Wang WD, Chen D, Jiang XY, Xu LF. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. Acad Radiol 2018;25:423-9. [PMID: 29198946 DOI: 10.1016/j.acra.2017.10.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
299 Nahon P, Kettaneh A, Lemoine M, Seror O, Barget N, Trinchet JC, Beaugrand M, Ganne-Carrié N. Liver stiffness measurement in patients with cirrhosis and hepatocellular carcinoma: a case-control study. Eur J Gastroenterol Hepatol. 2009;21:214-219. [PMID: 19212210 DOI: 10.1097/meg.0b013e32830eb8d7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
300 Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3069-3077 [PMID: 24695579 DOI: 10.3748/wjg.v20.i12.3069] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
301 Liu C, Wang Y, Yu X, Dong B, Zhou P, Ren H, Liang P. Is percutaneous microwave ablation of liver tumor safe for patients with renal dysfunction. European Journal of Radiology 2011;79:e103-7. [DOI: 10.1016/j.ejrad.2011.04.050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
302 Nahon P, Sutton A, Rufat P, Faisant C, Simon C, Barget N, Trinchet JC, Beaugrand M, Gattegno L, Charnaux N. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol. 2007;19:425-431. [PMID: 17413295 DOI: 10.1097/meg.0b013e3280120e2b] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
303 Weiss MJ, D'Angelica MI. Patient selection for hepatic resection for metastatic colorectal cancer. J Gastrointest Oncol 2012;3:3-10. [PMID: 22811864 DOI: 10.3978/j.issn.2078-6891.2012.001] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
304 Hasdemir DB, Dávila LA, Schweitzer N, Meyer BC, Koch A, Vogel A, Wacker F, Rodt T. Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. Diagn Interv Radiol 2017;23:217-22. [PMID: 28256449 DOI: 10.5152/dir.2016.16006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
305 Ying ZL, Li XJ, Dang H, Wang F, Xu XY. Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells. Exp Ther Med. 2014;7:1354-1358. [PMID: 24940438 DOI: 10.3892/etm] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
306 Li Z, Di C, Li S, Yang X, Nie G. Smart Nanotherapeutic Targeting of Tumor Vasculature. Acc Chem Res 2019;52:2703-12. [DOI: 10.1021/acs.accounts.9b00283] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 14.7] [Reference Citation Analysis]
307 Dehbidi S, Farokhizadeh Z, Karimi MH, Afshari A, Behmanesh M, Sanati MH, Geramizadeh B, Yaghobi R. Evaluation of microRNA Gene Polymorphisms in Liver Transplant Patients with Hepatocellular Carcinoma. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.102690] [Reference Citation Analysis]
308 Ajayi F, Jan J, Singal AG, Rich NE. Racial and Sex Disparities in Hepatocellular Carcinoma in the USA. Curr Hepatol Rep 2020;19:462-9. [PMID: 33828937 DOI: 10.1007/s11901-020-00554-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
309 Niravath P, Hayes T, Hilsenbeck S. Utility of screening for hepatocellular carcinoma among cirrhotics. Frontline Gastroenterol 2011;2:182-7. [PMID: 28839606 DOI: 10.1136/fg.2010.003244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
310 Chew SA, Moscato S, George S, Azimi B, Danti S. Liver Cancer: Current and Future Trends Using Biomaterials. Cancers (Basel) 2019;11:E2026. [PMID: 31888198 DOI: 10.3390/cancers11122026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
311 Kedarisetty CK, Bal S, Parida S, Jain M, Bhadoria AS, Varghese J, Venkataraman J. Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience. J Clin Exp Hepatol 2021;11:299-304. [PMID: 33994712 DOI: 10.1016/j.jceh.2020.10.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
312 Liu J, Gao Y, Yang B, Jia X, Zhai D, Li S, Zhang Q, Jing L, Wang Y, Du Z, Wang Y. Overexpression of Squamous Cell Carcinoma Antigen 1 Is Associated with the Onset and Progression of Human Hepatocellular Carcinoma. Archives of Medical Research 2015;46:133-41. [DOI: 10.1016/j.arcmed.2015.03.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
313 Lu L, Zeng J, Wen Z, Tang C, Xu N. Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults. Cochrane Database Syst Rev. 2019;2:CD012244. [PMID: 30776082 DOI: 10.1002/14651858.cd012244.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
314 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
315 Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
316 Soydal C, Keskin O, Kucuk ON, Ozkan E, Bilgic S, Idilman R, Kir MK. Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy. Ann Nucl Med. 2015;29:426-430. [PMID: 25783289 DOI: 10.1007/s12149-015-0962-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
317 Choi SH, Kim SY, Lee SS, Shim JH, Byun JH, Baek S, Lee M. Subtraction Images of Gadoxetic Acid–Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma. American Journal of Roentgenology 2017;209:584-91. [DOI: 10.2214/ajr.16.17211] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
318 Ma H, Liu J, Liu F. CT-guided single high-dose percutaneous acetic acid injection for small hepatocellular carcinoma: a long-term follow-up study. Eur J Radiol 2012;81:1184-6. [PMID: 21511422 DOI: 10.1016/j.ejrad.2011.03.063] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
319 Pinter M, Sieghart W, Reisegger M, Wrba F, Peck-Radosavljevic M. Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. Wien Klin Wochenschr 2011;123:61-4. [PMID: 21240686 DOI: 10.1007/s00508-010-1522-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
320 Al-Naamani K, Al-Hashami Z, Al-Siyabi O, Al-Moundri M, Al-Bahrani B, Al-Sinani S, Al-Zakwani I, Omar H, Al-Busafi SA, Al-Zuhaibi H, AlMamari A, Kamath BR, Al-Kalbani A, Burney IA. Hepatocellular Carcinoma in Oman: An analysis of 284 cases. Sultan Qaboos Univ Med J 2020;20:e316-22. [PMID: 33110647 DOI: 10.18295/squmj.2020.20.03.011] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
321 Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, Federici G, Gambardella L, Metrangolo S, Parisi G, Romano A, Scaramuzzino A, Tumino E, Silvestri A, Altomare E, Vignali C, Capria A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: A cohort study. World J Gastroenterol 2009; 15(15): 1843-1848 [PMID: 19370781 DOI: 10.3748/wjg.15.1843] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
322 Fan C, Jin G, Sun C, Ma D, Chen C, Qiao P, Wu D. Clinical characteristics, treatment patterns and survival outcome of hepatocellular carcinoma patients aged 70 years or older: a single-center retrospective study from China. Aging Clin Exp Res 2014;26:123-30. [PMID: 24129805 DOI: 10.1007/s40520-013-0142-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
323 Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Yamanaka K, Iida T, Taura K, Yasuchika K, Uemoto S. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:156-162. [PMID: 21850564 DOI: 10.1245/s10434-011-1990-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
324 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol 2015; 7(9): 1157-1167 [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
325 Moussa AM, Ziv E. Radiogenomics in Interventional Oncology. Curr Oncol Rep 2021;23:9. [PMID: 33387095 DOI: 10.1007/s11912-020-00994-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
326 Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol 2015; 7(26): 2648-2663 [PMID: 26609342 DOI: 10.4254/wjh.v7.i26.2648] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 16.6] [Reference Citation Analysis]
327 Chen D, Wang R, Meng X, Yan H, Jiang S, Feng R, Zhu K, Xu X, Dou X, Jin L. Prognostic value of serum γ-glutamyl transferase in unresectable hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization combined with conformal radiotherapy. Oncol Lett 2014;8:2298-304. [PMID: 25289109 DOI: 10.3892/ol.2014.2456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
328 Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol. 2009;50:351-357. [PMID: 19070395 DOI: 10.1016/j.jhep.2008.09.011] [Cited by in Crossref: 114] [Cited by in F6Publishing: 97] [Article Influence: 8.1] [Reference Citation Analysis]
329 Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, Weiss AA, Krahn MD. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection: Quality of life in HCV infection. Journal of Gastroenterology and Hepatology 2012;27:149-57. [DOI: 10.1111/j.1440-1746.2011.06813.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
330 Helling TS, Woodall CE 3rd. Referrals for surgical therapy in patients with hepatocellular carcinoma: a community experience. J Gastrointest Surg 2007;11:76-81. [PMID: 17390191 DOI: 10.1007/s11605-006-0073-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
331 Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C, Charnaux N, Ganne-Carrié N, Grando-Lemaire V, N’Kontchou G. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology. 2009;50:1484-1493. [PMID: 19731237 DOI: 10.1002/hep.23187] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
332 Elshaarawy O, Aman A, Zakaria HM, Zakareya T, Gomaa A, Elshimi E, Abdelsameea E. Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis. World J Gastrointest Oncol 2021; 13(5): 424-439 [PMID: 34040703 DOI: 10.4251/wjgo.v13.i5.424] [Reference Citation Analysis]
333 Jung AY, Lee JM, Choi SH, Kim SH, Lee JY, Kim SW, Han JK, Choi BI. CT features of an intraductal polypoid mass: Differentiation between hepatocellular carcinoma with bile duct tumor invasion and intraductal papillary cholangiocarcinoma. J Comput Assist Tomogr. 2006;30:173-181. [PMID: 16628028 DOI: 10.1097/00004728-200603000-00002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
334 Pitton MB, Kloeckner R, Herber S, Otto G, Kreitner KF, Dueber C. MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15(48): 6044-6051 [PMID: 20027676 DOI: 10.3748/wjg.15.6044] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
335 Lempinen M, Lyytinen I, Nordin A, Tervahartiala T, Mäkisalo H, Sorsa T, Isoniemi H. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma. Ann Med 2013;45:482-7. [PMID: 23962148 DOI: 10.3109/07853890.2013.823779] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
336 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
337 Choi SH, Byun JH, Lim YS, Yu E, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol 2016;64:1099-107. [PMID: 26820629 DOI: 10.1016/j.jhep.2016.01.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 9.8] [Reference Citation Analysis]
338 Kohi MP, Fidelman N, Naeger DM, LaBerge JM, Gordon RL, Kerlan RK. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol. 2013;24:68-73. [PMID: 23176968 DOI: 10.1016/j.jvir.2012.08.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
339 da Motta Girardi D, Correa TS, Crosara Teixeira M, Dos Santos Fernandes G. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. J Gastrointest Canc 2018;49:227-36. [DOI: 10.1007/s12029-018-0121-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
340 Nahon P, Sutton A, Pessayre D, Rufat P, Charnaux N, Trinchet JC, Beaugrand M, Deugnier Y. Do genetic variations in antioxidant enzymes influence the course of hereditary hemochromatosis? Antioxid Redox Signal. 2011;15:31-38. [PMID: 20673159 DOI: 10.1089/ars.2010.3529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
341 Chu F, Morris D. Single centre experience of liver resection for hepatocellular carcinoma in patients outside transplant criteria. European Journal of Surgical Oncology (EJSO) 2006;32:568-72. [DOI: 10.1016/j.ejso.2006.02.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
342 Ruff SM, Rothermel LD, Diggs LP, Wach MM, Ayabe RI, Martin SP, Boulware D, Anaya D, Davis JL, Mullinax JE, Hernandez JM. Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection. HPB (Oxford) 2020;22:1004-10. [PMID: 31734237 DOI: 10.1016/j.hpb.2019.10.1531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
343 Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:23-33. [PMID: 21115578 DOI: 10.1634/theoncologist.2010-s4-23] [Cited by in Crossref: 79] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
344 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Huo TI. Hepatocellular carcinoma in uremic patients: is there evidence for an increased risk of mortality? J Gastroenterol Hepatol. 2013;28:348-356. [PMID: 23190248 DOI: 10.1111/jgh.12062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
345 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
346 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
347 Kim CK, Choi D, Lim HK, Kim SH, Lee WJ, Kim MJ, Lee JY, Jeon YH, Lee J, Lee SJ. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. Eur J Radiol. 2005;56:66-73. [PMID: 15913940 DOI: 10.1016/j.ejrad.2005.03.023] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
348 Hong W, Hu Y, Fan Z, Gao R, Yang R, Bi J, Hou J. In silico identification of EP400 and TIA1 as critical transcription factors involved in human hepatocellular carcinoma relapse. Oncol Lett 2020;19:952-64. [PMID: 31897208 DOI: 10.3892/ol.2019.11171] [Reference Citation Analysis]
349 Trinchet J, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Goria O, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Blanc J, Abergel A, Serfaty L, Mallat A, Grangé J, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S; and the ANRS CO12 CirVir Group. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort): HEPATOLOGY, Vol. XX, No. X, 2015 TRINCHET ET AL. Hepatology 2015;62:737-50. [DOI: 10.1002/hep.27743] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 8.7] [Reference Citation Analysis]
350 Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 2010;16:1186-94. [PMID: 20879017 DOI: 10.1002/lt.22129] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
351 Chen J, Liang J, Liu S, Song S, Guo W, Shen F. Differential regulation of AKT1 contributes to survival and proliferation in hepatocellular carcinoma cells by mediating Notch1 expression. Oncol Lett 2018;15:6857-64. [PMID: 29725418 DOI: 10.3892/ol.2018.8193] [Reference Citation Analysis]
352 Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation. 2007;75:843-852. [PMID: 17999742 DOI: 10.1111/j.1432-0436.2007.00235.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
353 Stocker D, Marquez HP, Wagner MW, Raptis DA, Clavien PA, Boss A, Fischer MA, Wurnig MC. MRI texture analysis for differentiation of malignant and benign hepatocellular tumors in the non-cirrhotic liver. Heliyon 2018;4:e00987. [PMID: 30761374 DOI: 10.1016/j.heliyon.2018.e00987] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
354 Tsoulfas G, Agorastou P, Tooulias A, Marakis GN. Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review. Int Surg 2014;99:779-86. [PMID: 25437587 DOI: 10.9738/INTSURG-D-13-00122.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
355 Lee EJ, Yang SH, Kim KJ, Cha H, Lee SJ, Kim JH, Song J, Chun KH, Seong J. Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma. Cancer Res Treat 2018;50:646-57. [PMID: 28724284 DOI: 10.4143/crt.2016.550] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
356 Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053-1063. [PMID: 22432445 DOI: 10.1111/j.1478-3231.2012.02792.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
357 Huang H, Zhang XF, Zhou HJ, Xue YH, Dong QZ, Ye QH, Qin LX. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci. 2010;101:1314-1319. [PMID: 20345480 DOI: 10.1111/j.1349-7006.2010.01524.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
358 Jung AY, Lee JM, Choi SH, Kim SH, Lee JY, Kim SW, Han JK, Choi BI. Computed tomography features of an intraductal polypoid mass: differentiation between hepatocellular carcinoma with bile duct tumor invasion and intraductal papillary cholangiocarcinoma. J Comput Assist Tomogr 2006;30:18-24. [PMID: 16365567 DOI: 10.1097/01.rct.0000188837.71136.fe] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
359 Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int. 2010;4:396-405. [PMID: 20305756 DOI: 10.1007/s12072-009-9157-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
360 Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005;3:75-84. [PMID: 15645408 DOI: 10.1016/s1542-3565(04)00443-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
361 Al-gayyar MM, Ebrahim MA, Shams ME. Measuring serum levels of glycosaminoglycans for prediction and using viscum fraxini-2 for treatment of patients with hepatocellular carcinoma. Journal of Pharmacy Research 2013;7:571-5. [DOI: 10.1016/j.jopr.2013.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
362 Dyhl-Polk A, Mikkelsen MK, Ladekarl M, Nielsen DL. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. J Clin Med 2021;10:2662. [PMID: 34208788 DOI: 10.3390/jcm10122662] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
363 Song B, Zhen S, Meng F. T cell inflammation profile after surgical resection may predict tumor recurrence in HBV-related hepatocellular carcinoma. Int Immunopharmacol 2016;41:35-41. [PMID: 27792920 DOI: 10.1016/j.intimp.2016.10.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
364 Xu HX, Liu GJ, Lu MD, Xie XY, Xu ZF, Zheng YL, Liang JY. Characterization of small focal liver lesions using real-time contrast-enhanced sonography: diagnostic performance analysis in 200 patients. J Ultrasound Med 2006;25:349-61. [PMID: 16495496 DOI: 10.7863/jum.2006.25.3.349] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
365 Cui J, Nan KJ, Tian T, Guo YH, Zhao N, Wang L. Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture. World J Gastroenterol 2007; 13(41): 5432-5439 [PMID: 17907285 DOI: 10.3748/wjg.v13.i41.5432] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
366 White SA, Manas DM, Farid SG, Prasad KR. Optimal treatment for hepatocellular carcinoma in the cirrhotic liver. Ann R Coll Surg Engl 2009;91:545-50. [PMID: 19833013 DOI: 10.1308/003588409X464649] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
367 Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK; Asia-Pacific Hepatocellular Carcinoma Trials Group. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 2016;16:856. [PMID: 27821083 DOI: 10.1186/s12885-016-2868-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
368 Gharib AF, Karam RA, Pasha HF, Radwan MI, Elsawy WH. Polymorphisms of hemochromatosis, and alpha-1 antitrypsin genes in Egyptian HCV patients with and without hepatocellular carcinoma. Gene. 2011;489:98-102. [PMID: 21925577 DOI: 10.1016/j.gene.2011.08.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
369 Butcher DA, Brandis KJ, Wang H, Spannenburg L, Bridle KR, Crawford DH, Liang X. Long-term survival and postoperative complications of pre-liver transplantation transarterial chemoembolisation in hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2021:S0748-7983(21)00743-5. [PMID: 34774394 DOI: 10.1016/j.ejso.2021.09.017] [Reference Citation Analysis]
370 Ziv E, Zhang Y, Kelly L, Nikolovski I, Boas FE, Erinjeri JP, Cai L, Petre EN, Brody LA, Covey AM, Getrajdman G, Harding JJ, Sofocleous C, Abou-Alfa GK, Solomon SB, Brown KT, Yarmohammadi H. NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. Radiology 2020;297:225-34. [PMID: 32780006 DOI: 10.1148/radiol.2020200201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
371 Campos-Correia D, Cruz J, Matos AP, Figueiredo F, Ramalho M. Magnetic resonance imaging ancillary features used in Liver Imaging Reporting and Data System: An illustrative review. World J Radiol 2018; 10(2): 9-23 [PMID: 29507710 DOI: 10.4329/wjr.v10.i2.9] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
372 Kwee SA, Wong LL, Sato MM, Acoba JD, Rho YS, Srivastava A, Landsittel DP. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation. J Vasc Interv Radiol 2021;32:1258-1266.e6. [PMID: 34242775 DOI: 10.1016/j.jvir.2021.07.001] [Reference Citation Analysis]
373 Wei Y, Yi Y, Tao C, Ye W, Zhao W. Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas. Cancer Manag Res 2019;11:8475-86. [PMID: 31572002 DOI: 10.2147/CMAR.S201744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
374 Wang J, Xu Y, Wang Y, Zhang X, Zhang G. Further Study of Circulating Antibodies to P16, CD25 and FOXP3 in Hepatocellular Carcinoma. Onco Targets Ther 2019;12:10487-93. [PMID: 31819529 DOI: 10.2147/OTT.S226404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
375 Salem ME, Jain N, Dyson G, Taylor S, El-Refai SM, Choi M, Shields AF, Critchfield J, Philip PA. Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization. ISRN Oncol 2013;2013:538376. [PMID: 24167742 DOI: 10.1155/2013/538376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
376 Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53:108-117. [PMID: 20451283 DOI: 10.1016/j.jhep.2010.01.038] [Cited by in Crossref: 106] [Cited by in F6Publishing: 102] [Article Influence: 8.8] [Reference Citation Analysis]
377 Liu GJ, Xu HX, Xie XY, Xu ZF, Zheng YL, Liang JY, Lu MD, Moriyasu F. Does the echogenicity of focal liver lesions on baseline gray-scale ultrasound interfere with the diagnostic performance of contrast-enhanced ultrasound? Eur Radiol 2009;19:1214-22. [PMID: 19137313 DOI: 10.1007/s00330-008-1251-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
378 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
379 Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocellular carcinoma. Int J Hepatol. 2013;2013:419302. [PMID: 24455285 DOI: 10.1155/2013/419302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
380 Huang ST, Hsu WF, Huang HS, Yen JH, Lin MC, Peng CY, Yen HR. Improved Survival in Hepatocellular Carcinoma Patients with Cardiac Arrhythmia by Amiodarone Treatment through Autophagy. Int J Mol Sci 2019;20:E3978. [PMID: 31443312 DOI: 10.3390/ijms20163978] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
381 Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008;2:453-62. [PMID: 19707376 DOI: 10.2147/btt.s3254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
382 Zane KE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2021;13:5430. [PMID: 34771593 DOI: 10.3390/cancers13215430] [Reference Citation Analysis]
383 Yuan BH, Yuan WP, Li RH, Xiang BD, Gong WF, Li LQ, Zhong JH. Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. Tumour Biol. 2016;37:2435-2441. [PMID: 26383523 DOI: 10.1007/s13277-015-4091-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
384 Wong J, Lee KF, Yu SC, Lee PS, Cheung YS, Chong CN, Ip PC, Lai PB. Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results. HPB (Oxford) 2013;15:595-601. [PMID: 23458320 DOI: 10.1111/hpb.12014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
385 Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems. PLoS One 2014;9:e99115. [PMID: 24906132 DOI: 10.1371/journal.pone.0099115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
386 da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31:264. [PMID: 25273866 DOI: 10.1007/s12032-014-0264-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
387 Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395:19-26. [PMID: 18538135 DOI: 10.1016/j.cca.2008.05.010] [Cited by in Crossref: 136] [Cited by in F6Publishing: 126] [Article Influence: 9.7] [Reference Citation Analysis]
388 Malagó M, Sotiropoulos GC, Nadalin S, Valentin-Gamazo C, Paul A, Lang H, Radtke A, Saner F, Molmenti E, Beckebaum S. Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report. Liver Transpl. 2006;12:934-940. [PMID: 16528715 DOI: 10.1002/lt.20677] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
389 Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology. 2006;44:7-14. [PMID: 16799965 DOI: 10.1002/hep.21258] [Cited by in Crossref: 167] [Cited by in F6Publishing: 138] [Article Influence: 10.4] [Reference Citation Analysis]
390 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Fonseca AL, Cha CH. Hepatocellular carcinoma: a comprehensive overview of surgical therapy. J Surg Oncol. 2014;110:712-719. [PMID: 24894746 DOI: 10.1002/jso.23673] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
392 Nagi NMS, Khair YAM, Abdalla AME. Capacity of gold nanoparticles in cancer radiotherapy. Jpn J Radiol 2017;35:555-61. [DOI: 10.1007/s11604-017-0671-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
393 Chen H, Shi D, Wang Y, Zhang L, Zhang Q, Wang B, Xia C. The advances in applying inorganic fluorescent nanomaterials for the detection of hepatocellular carcinoma and other cancers. RSC Adv 2015;5:79572-84. [DOI: 10.1039/c5ra14853g] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
394 Guzman G. Overview of liver pathology. Dis Mon 2008;54:419-31. [PMID: 18570912 DOI: 10.1016/j.disamonth.2008.03.007] [Reference Citation Analysis]
395 Sirohi B, Shrikhande SV, Gaikwad V, Patel A, Patkar S, Goel M, Bal M, Sharma A, Shrimali RK, Bhatia V, Kulkarni S, Srivastava DN, Kaur T, Dhaliwal RS, Rath GK; Indian Council of Medical Research Guidelines Working Group. Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian J Med Res 2020;152:468-74. [PMID: 33707388 DOI: 10.4103/ijmr.IJMR_404_20] [Reference Citation Analysis]
396 Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis. Journal of Hepatology 2010;52:380-8. [DOI: 10.1016/j.jhep.2009.12.004] [Cited by in Crossref: 186] [Cited by in F6Publishing: 164] [Article Influence: 15.5] [Reference Citation Analysis]
397 Moeckli B, Majno P, Orci LA, Peloso A, Toso C. Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective. Semin Liver Dis 2021;41:172-81. [PMID: 33957694 DOI: 10.1055/s-0041-1723032] [Reference Citation Analysis]
398 Kiszkaą J, Karczmarek-Borowska B. Radioembolization treatment for liver metastases. Contemp Oncol (Pozn) 2017;21:274-8. [PMID: 29416432 DOI: 10.5114/wo.2017.72153] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
399 Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines (Basel) 2020;8:E247. [PMID: 32456200 DOI: 10.3390/vaccines8020247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
400 Ballı HT, Aikimbaev K. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety. Diagn Interv Radiol 2020;26:482-7. [PMID: 32815520 DOI: 10.5152/dir.2020.19410] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
401 Xu ZF, Xie XY, Kuang M, Liu GJ, Chen LD, Zheng YL, Lu MD. Percutaneous radiofrequency ablation of malignant liver tumors with ultrasound and CT fusion imaging guidance. J Clin Ultrasound. 2014;42:321-330. [PMID: 24615771 DOI: 10.1002/jcu.22141] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
402 Belli G, D'Agostino A, Fantini C, Cioffi L, Belli A, Russolillo N, Langella S. Laparoscopic radiofrequency ablation combined with laparoscopic liver resection for more than one HCC on cirrhosis. Surg Laparosc Endosc Percutan Tech. 2007;17:331-334. [PMID: 17710062 DOI: 10.1097/SLE.0b013e31806d9c65] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
403 Hilmi M, Vienot A, Rousseau B, Neuzillet C. Immune Therapy for Liver Cancers. Cancers (Basel) 2019;12:E77. [PMID: 31892230 DOI: 10.3390/cancers12010077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
404 Lambert B, Sturm E, Mertens J, Oltenfreiter R, Smeets P, Troisi R, Van Vlierberghe H, Defreyne L. Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging 2011;38:2117-24. [DOI: 10.1007/s00259-011-1881-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
405 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Reference Citation Analysis]
406 Baheti AD, Dunham GM, Ingraham CR, Moshiri M, Lall C, Park JO, Li D, Katz DS, Madoff DC, Bhargava P. Clinical implications for imaging of vascular invasion in hepatocellular carcinoma. Abdom Radiol 2016;41:1800-10. [DOI: 10.1007/s00261-016-0763-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
407 Capussotti L, Ferrero A, Viganò L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg. 2006;30:992-999. [PMID: 16736327 DOI: 10.1007/s00268-005-0524-9.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
408 Zhao HC, Wu RL, Liu FB, Zhao YJ, Wang GB, Zhang ZG, Huang F, Xie K, Geng XP. A retrospective analysis of long term outcomes in patients undergoing hepatic resection for large (>5 cm) hepatocellular carcinoma. HPB (Oxford) 2016;18:943-9. [PMID: 27640098 DOI: 10.1016/j.hpb.2016.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
409 Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JH. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology 2015;277:594-603. [DOI: 10.1148/radiol.2015142481] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
410 Blum HE. Treatment of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2005;19:129-45. [DOI: 10.1016/j.bpg.2004.11.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
411 Kim Y, Stahl CC, Makramalla A, Olowokure OO, Ristagno RL, Dhar VK, Schoech MR, Chadalavada S, Latif T, Kharofa J, Bari K, Shah SA. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery. 2017;162:1250-1258. [PMID: 29033224 DOI: 10.1016/j.surg.2017.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
412 Famularo S, Giani A, Di Sandro S, Sandini M, Giacomoni A, Pinotti E, Lauterio A, Gianotti L, De Carlis L, Romano F. Does the Pringle maneuver affect survival and recurrence following surgical resection for hepatocellular carcinoma? A western series of 441 patients. J Surg Oncol 2018;117:198-206. [DOI: 10.1002/jso.24819] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
413 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445-452. [PMID: 17683486 DOI: 10.1111/j.1440-1746.2007.05075.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
414 Gan G, Shi Z, Liu D, Zhang S, Zhu H, Wang Y, Mi J. 3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness. Cell Death Discov 2021;7:173. [PMID: 34230478 DOI: 10.1038/s41420-021-00561-6] [Reference Citation Analysis]
415 Taurà P, Fuster J, Mercadal J, Martinez-palli G, Fondevila C, Blasi A, Balust J, Garcia-valdecasas J. The use of β-adrenergic drugs improves hepatic oxygen metabolism in cirrhotic patients undergoing liver resection. Journal of Hepatology 2010;52:340-7. [DOI: 10.1016/j.jhep.2009.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
416 Torzilli G. 17th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists. Future Oncol 2007;3:605-7. [PMID: 18041911 DOI: 10.2217/14796694.3.6.605] [Reference Citation Analysis]
417 Zhu SL, Ke Y, Peng YC, Ma L, Li H, Li LQ, Zhong JH. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. PLoS One. 2014;9:e115834. [PMID: 25541684 DOI: 10.1371/journal.pone.0115834] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
418 Longo KC, Knott EA, Watson RF, Swietlik JF, Vlaisavljevich E, Smolock AR, Xu Z, Cho CS, Mao L, Lee FT Jr, Ziemlewicz TJ. Robotically Assisted Sonic Therapy (RAST) for Noninvasive Hepatic Ablation in a Porcine Model: Mitigation of Body Wall Damage with a Modified Pulse Sequence. Cardiovasc Intervent Radiol 2019;42:1016-23. [PMID: 31041527 DOI: 10.1007/s00270-019-02215-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
419 Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res 2020;9:F1000 Faculty Rev-620. [PMID: 32595940 DOI: 10.12688/f1000research.24543.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
420 Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am. 2010;90:803-816. [PMID: 20637949 DOI: 10.1016/j.suc.2010.04.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
421 Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, Hori Y, Hishikawa Y, Ku Y, Murakami M. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer. 2011;117:4890-4904. [PMID: 21495022 DOI: 10.1002/cncr.26134] [Cited by in Crossref: 94] [Cited by in F6Publishing: 74] [Article Influence: 8.5] [Reference Citation Analysis]
422 Feng J, Zhu R, Feng D, Yu L, Zhao D, Wu J, Yuan C, Chen J, Zhang Y, Zheng X. Prediction of Early Recurrence of Solitary Hepatocellular Carcinoma after Orthotopic Liver Transplantation. Sci Rep 2019;9:15855. [PMID: 31676847 DOI: 10.1038/s41598-019-52427-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
423 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 164] [Article Influence: 27.8] [Reference Citation Analysis]
424 Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Baker T, Kulik L, Gupta R, Abecassis M, Benson AB, Omary R, Millender L, Kennedy A, Salem R. Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization. International Journal of Radiation Oncology*Biology*Physics 2011;79:163-71. [DOI: 10.1016/j.ijrobp.2009.10.062] [Cited by in Crossref: 131] [Cited by in F6Publishing: 109] [Article Influence: 11.9] [Reference Citation Analysis]
425 Borowski AM, Frangos A, Mccann JW, Brown DB. Pressure Wire Assessment of Hemodynamic Alterations after Chemoembolization of Hepatocellular Carcinoma. Academic Radiology 2013;20:1037-40. [DOI: 10.1016/j.acra.2013.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
426 Bayram S. RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population. Gene 2012;498:264-9. [PMID: 22394463 DOI: 10.1016/j.gene.2012.02.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
427 Do RK, Rusinek H, Taouli B. Dynamic contrast-enhanced MR imaging of the liver: current status and future directions. Magn Reson Imaging Clin N Am. 2009;17:339-349. [PMID: 19406362 DOI: 10.1016/j.mric.2009.01.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
428 Yilma M, Saxena V, Mehta N. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Curr Gastroenterol Rep 2022. [PMID: 35142988 DOI: 10.1007/s11894-022-00835-8] [Reference Citation Analysis]
429 Bruno CM, Valenti M, Bertino G, Ardiri A, Amoroso A, Consolo M, Mazzarino CM, Neri S. Relationship between circulating interleukin-10 and histological features in patients with chronic C hepatitis. Ann Saudi Med. 2011;31:360-364. [PMID: 21808111 DOI: 10.4103/0256-4947.83215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
430 Spangenberg HC, Thimme R, Von Weizsäcker F, Blum HE. [Best supportive care of hepatocellular carcinoma]. Internist (Berl) 2004;45:777-85. [PMID: 15160245 DOI: 10.1007/s00108-004-1226-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
431 Brennan IM, Ahmed M. Imaging features following transarterial chemoembolization and radiofrequency ablation of hepatocellular carcinoma. Semin Ultrasound CT MR. 2013;34:336-351. [PMID: 23895906 DOI: 10.1053/j.sult.2013.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
432 Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
433 Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M. Reply to Letter: “Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on ‘Surgical Misinterpretation’ of the BCLC Staging System”: Real Misinterpretation or Lack of Clarity Within the BCLC? Ann Surg. 2015;262:e18-e19. [PMID: 24263335 DOI: 10.1097/sla.0000000000000383] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
434 Qu LS, Jin F, Guo YM, Liu TT, Xue RY, Huang XW, Xu M, Chen TY, Ni ZP, Shen XZ. Nine susceptibility loci for hepatitis B virus-related hepatocellular carcinoma identified by a pilot two-stage genome-wide association study. Oncol Lett. 2016;11:624-632. [PMID: 26870257 DOI: 10.3892/ol.2015.3958] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
435 Murtha-Lemekhova A, Fuchs J, Schulz E, Sterkenburg AS, Mayer P, Pfeiffenberger J, Hoffmann K. Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features. J Hepatocell Carcinoma 2021;8:1269-79. [PMID: 34712626 DOI: 10.2147/JHC.S328198] [Reference Citation Analysis]
436 Xu WJ, Guo BL, Han YG, Shi L, Ma WS. Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels. Tumour Biol. 2014;35:12069-12074. [PMID: 25209179 DOI: 10.1007/s13277-014-2506-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
437 Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee., Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 2011;22:265-78. [PMID: 21353979 DOI: 10.1016/j.jvir.2010.10.029] [Cited by in Crossref: 148] [Cited by in F6Publishing: 140] [Article Influence: 13.5] [Reference Citation Analysis]
438 Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, Rodriguez-Torres M, Giantonio B, Fox NL, Wissel P, Egger J, Ding M, Kalyani RN, Humphreys R, Gribbin M, Sun W. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Ann Oncol. 2016;27:680-687. [PMID: 26802147 DOI: 10.1093/annonc/mdw004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
439 Hui TC, Kwan J, Pua U. Advanced Techniques in the Percutaneous Ablation of Liver Tumours. Diagnostics (Basel) 2021;11:585. [PMID: 33805107 DOI: 10.3390/diagnostics11040585] [Reference Citation Analysis]
440 Chen HA, Kuo TC, Tseng CF, Ma JT, Yang ST, Yen CJ, Yang CY, Sung SY, Su JL. Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. Hepatology. 2016;64:1637-1651. [PMID: 27530187 DOI: 10.1002/hep.28773] [Cited by in Crossref: 45] [Cited by in F6Publishing: 56] [Article Influence: 7.5] [Reference Citation Analysis]
441 Seinstra BA, van Delden OM, van Erpecum KJ, van Hillegersberg R, Mali WP, van den Bosch MA. Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging. 2010;1:167-181. [PMID: 23100194 DOI: 10.1007/s13244-010-0027-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
442 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 108] [Article Influence: 10.3] [Reference Citation Analysis]
443 Lim KC, Wang VW, Siddiqui FJ, Shi L, Chan ES, Oh HC, Tan SB, Chow PK. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology. 2015;61:227-237. [PMID: 24638991 DOI: 10.1002/hep.27135] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
444 Berretta M, Di Benedetto F, Dal Maso L, Cacopardo B, Nasti G, Facchini G, Bearz A, Spina M, Garlassi E, De Re V, Fiorica F, Lleshi A, Tirelli U. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anti-Cancer Drugs 2013;24:212-8. [DOI: 10.1097/cad.0b013e32835c032f] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.9] [Reference Citation Analysis]
445 Bakr S, Echegaray S, Shah R, Kamaya A, Louie J, Napel S, Kothary N, Gevaert O. Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study. J Med Imaging (Bellingham) 2017;4:041303. [PMID: 28840174 DOI: 10.1117/1.JMI.4.4.041303] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
446 Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2005;128:1752-1764. [PMID: 15887162 DOI: 10.1053/j.gastro.2005.03.033] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 5.5] [Reference Citation Analysis]
447 Chen X, Zhuang J, Kolb JF, Schoenbach KH, Beebe SJ. Long term survival of mice with hepatocellular carcinoma after pulse power ablation with nanosecond pulsed electric fields. Technol Cancer Res Treat. 2012;11:83-93. [PMID: 22181334 DOI: 10.7785/tcrt.2012.500237] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
448 Shirata C, Hasegawa K, Kokudo T, Yamashita S, Yamamoto S, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, Kokudo N. Liver Resection for Hepatocellular Carcinoma in Patients with Renal Dysfunction. World J Surg. 2018;42:4054-4062. [PMID: 29947980 DOI: 10.1007/s00268-018-4698-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
449 Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862-1868. [PMID: 15870713 DOI: 10.1038/sj.bjc.6602590] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 6.8] [Reference Citation Analysis]
450 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
451 Shams MEE, Al-gayyar MMH, Barakat EAME, Ebrahim MA, El-shishtawy MM. Circulating adiponectin: a potential prognostic marker for hepatocellular carcinoma. Chin -Ger J Clin Oncol 2011;10:570-4. [DOI: 10.1007/s10330-011-0859-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
452 Clasen S, Pereira P. Interventionelle Kombinationstherapien. Radiologe 2007;47:1072-82. [DOI: 10.1007/s00117-007-1589-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
453 Yang H, Chen G, Fang F, Liu Z, Hiu Yan Lau S, Zhang J, Lau WY, Yang L. Dickkopf-1: As a Diagnostic and Prognostic Serum Marker for Early Hepatocellular Carcinoma. Int J Biol Markers 2013;28:286-97. [DOI: 10.5301/jbm.5000015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
454 Ho WJ, Sharma G, Zhu Q, Stein-O'Brien G, Durham J, Anders R, Popovic A, Mo G, Kamel I, Weiss M, Jaffee E, Fertig EJ, Yarchoan M. Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. J Immunother Cancer 2020;8:e000932. [PMID: 33219090 DOI: 10.1136/jitc-2020-000932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]